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ABSTRACT [1,2,3]Triazolo[4,5-h][1,6]naphthyridines and [1,3]oxazolo[5,4-
h][1,6]naphthyridines were synthesized with the aim to investigate their photocytotoxic activity. 
Upon irradiation, oxazolo-naphtapyridines induced light-dependent cell death at nanomolar/low 
micromolar concentrations (EC50 0.01–6.59 μM). The most photocytotoxic derivative showed 
very high selectivity and photocytotoxicity indexes (SI=72-86, PTI>5000), along with a triplet 
excited state with exceptionally long lifetime (18.0 μs) and high molar absorptivity (29781±180 
M-1cm-1 at λmax 315 nm). The light-induced production of ROS promptly induced an unquenchable 
apoptotic process selectively in tumor cells, with mitochondrial and lysosomal involvement. 
Altogether, these results demonstrate that the most active compound acts as a promising singlet 
oxygen sensitizer for biological applications.  
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1. Introduction 
Naphthyridines (also known as pyridopyridines or diazanaphtalenes) are nitrogen heterocyclic 
compounds widely used in agriculture, in analytical chemistry, in diagnostics and for the 
treatment of different human diseases. [1]  
Among the six possible isomers (1,5-, 1,6-, 1,7-, 1,8- 2,6- and 2,7-pyridopyridines), 
[1,6]naphthyridines are endowed with interesting biological properties including antibacterial, [2, 
3] and anticonvulsant activity. [4] They have also been used as potent antiviral agents against 
both the human cytomegalovirus (HCMV) [5-7] and human immunodeficiency virus-1 (HIV-1). 
In fact, 8-hydroxy[1,6]naphthyridines 1 and 2 (Chart 1) proved to reduce HIV-1 integrase 
activity and to inhibit 95% of the spread of viral infection in cell culture at 0.39 μM and 18.6 nM 
respectively. [8,9] Further studies revealed that new derivatives of type 3, obtained from 
modification of the decoration of the lead structure at the 8-position, were endowed with 
significant cytotoxicity against a panel of cancer cell lines and inhibited selected oncogenic 
kinases. [10] FGFR-1 and VEGFR-2 kinases inhibitory activities at low nanomolar level were 
also exhibited by 7-acetamido[1,6]naphthyridines (4) synthetized by Thompson et al. [11,12] 
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Chart 1. Structures of [1,6]naphthyridine derivatives 1-4. 
 
Thus, considering the interesting properties showed by the [1,6]naphthyridine scaffold we 
synthetized tricyclic systems of type 5-8 (Chart 2) in which the triazole or oxazole moieties are 
annelated to the diazabicyclic portion. These new ring systems can be also regarded as hetero-
analogues of quinolines of type 9 and 10, potent photosensitizers previously reported by us, 
containing a pyrrole and a pyrazole ring respectively. [13-16] In particular, one class of 
pyrroloquinolones (9), upon light activation at a proper wavelength, showed potent growth 
inhibitory activity at submicromolar level (0.5-7.2 μM). Cellular photocytotoxicity was related to 
production of reactive oxygen species (ROS) with the involvement of both mitochondria and 
lysosomes, alteration of the cell cycle profile and membrane lipid peroxidation, without DNA 
photodamage. Condensation of the quinoline moiety to the pyrazole ring, led to pyrazolo[3,4-
h]quinolines (10); this structural modification led to the improvement of photocytotoxicity with 
growth inhibition of 50% of the cell population (GI50) reaching nanomolar level (0.04-14.52 μM). 
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Derivatives 10 were able to generate high levels of superoxide anion and singlet oxygen, 
suggesting involvement of both type I and type II oxygen-dependent photosensitization 
mechanisms. [16] 
More recently we have studied pyrrolo[3',2':6,7]cyclohepta[1,2-d]pyrimidines (11) and 
pyrrolo[3’,2’:6,7]cyclohepta[1,2-b]pyridines (12) which showed very promising antitumor 
properties. [17,18] Upon photoactivation with light of the proper wavelength, they showed 
cytotoxic effect at 0.06–4.96 μM and 0.19–10.70 μM respectively, inducing apoptosis associated 
with rapid and massive production of large amounts of ROS, mitochondrial morphology 
modifications and activation of lysosomes. Unfortunately, although these two classes of 
derivatives were endowed with potent photocytotoxic activity, they were not very selective for 
tumor cell lines. 
. 
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Chart 2. Structures of [1,2,3]triazolo[4,5-h][1,6]naphthyridines (5, 7), [1,3]oxazolo[5,4-
h][1,6]naphthyridines (6, 8), pyrroloquinolines (9), pyrazoloquinolines (10), 
pyrrolo[3',2':6,7]cyclohepta[1,2-d]pyrimidines (11) and pyrrolo[3’,2’:6,7]cyclohepta[1,2-
b]pyridines (12). 
 
Thus, as part of our search for nitrogen heterocycles [19-37] and considering that the antitumor 
effect of [1,6]naphthyridines has been widely investigated, but no examples of their 
photochemotherapeutic activity have been reported so far, herein we report the synthesis of the 
new ring systems [1,2,3]triazolo[4,5-h][1,6]naphthyridines 5a-l, 7a-c, and [1,3]oxazolo[5,4-
h][1,6]naphthyridines 6a-l, 8a-c with the aim of investigating their antiproliferative effect 
either in the dark and under light irradiation. 
 
2.  Results and Discussion 
 
2.1.  Chemistry 
The key intermediates 7-amino-5-methyl-3-substituted-3H-[1,2,3]triazolo[4,5-b]pyridine-6-
carbaldehydes (23a-c) and 7-amino-5-methyl-2-substituted-[1,3]oxazolo[5,4-b]pyridine-6-
carbaldehydes (24a-c) were prepared starting from the suitable 5-amino-1-substituted-1H-1,2,3-
triazole-4-carbonitrile derivatives (17a-c) or 5-amino-2-substituted-[1,3]oxazole-4-carbonitrile 
derivatives (18a-c) respectively (Scheme 1). 
In particular, compounds 17a-c were obtained through a 1,3-dipolar cycloaddition of the proper 
azido-derivatives (13a-c) with malononitrile (14) in the presence of sodium ethoxide. 5-Amino-
2-substituted-[1,3]oxazole-4-carbonitrile derivatives 18a-c were prepared through the van 
Leusen oxazole synthesis, according to the general method reported by Freeman and Kim. [38] 
Thus a solution of commercially available aminomalononitrile tosylate (16) in 1-methyl-2-
pyrrolidone was reacted with the proper benzoyl chloride (15a-c). The desired compounds 17a-
c and 18a-c were subsequently refluxed with ethyl acetoacetate, in the presence of stannic 
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chloride as strong Lewis acid, allowing the isolation of 7-amino-5-methyl-3-substituted-3H-
[1,2,3]triazolo[4,5-b]pyridine-6-carboxylate derivatives (19a-c) and ethyl 7-amino-5-methyl-2-
substituted[1,3]oxazolo[5,4-b]pyridine-6-carboxylates (20a-c). These latter were subjected to 
reduction of the ethoxycarbonyl group with lithium aluminium hydride in THF to give 
compounds 21a-c and 22a-c, which were in turn submitted to oxidation reaction with Dess-
Martin periodinane in dichloromethane, leading to the corresponding key intermediate o-
aminoaldehydes 23a-c and 24a-c which were used without further purification. 
 
  
 
Scheme 1. Synthesis of key intermediates 23a-c, and 24a-c. 
 
Reagents: (i) EtONa, ethanol, 0 °C-rt, 12 h, 60-70%; (ii) 1-methyl-2-pyrrolidinone, rt, 12 h, 51-
79%; (iii) ethyl acetoacetate, toluene, stannic chloride, reflux, 4 h, 45-62% (for derivatives 19a-
c), 45-65% (for derivatives 20a-c); (iv) LiAlH4, THF, 0 °C-rt, 12 h, 58-92% (for derivatives 
21a-c), 55-80% (for derivatives 22a-c); (v) Dess-Martin periodinane, DCM, rt, 5 h. 
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Scheme 2. Synthesis of naphthyridine derivatives 5a-l, 6a-l and naphthyridine-8-one 
derivatives 7a-c, 8a-c. 
 
Reagents: (i) KOH, ethanol and suitable ketone, or KOH and acetone (for derivatives 5d, 5h, 
5l,  6d, 6h, 6l) reflux, 12 h, 42-65% (for derivatives 5a-l), 40-58% (for derivatives 6a-l); (ii) 
K2CO3, ethanol, reflux, 12 h, 40-60% (for derivatives 7a-c), 45-62% (for derivatives 8a-c).  
 
Cyclization to naphthyridine derivatives 5a-l and 6a-l was achieved through Friendlander 
condensation of compounds 23a-c and 24a-c, respectively, with acetophenone or substituted 
acetophenones, such as 2-methoxy-acetophenone, 4-methoxy-acetophenone and acetone, in basic 
media (Table 1).  
 
 
 
 
 
Table 1. Naphthyridine derivatives 5a-l and 6a-l. 
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Compd R R 1 Compd R R 1 
5a Ph Ph 6a Ph Ph 
5b Ph 2-OMe-Ph 6b Ph 2-OMe-Ph 
5c Ph 4-OMe-Ph 6c Ph 4-OMe-Ph 
5d Ph Me 6d Ph Me 
5e 4-OMe-Ph Ph 6e 4-OMe-Ph Ph 
5f 4-OMe-Ph 2-OMe-Ph 6f 4-OMe-Ph 2-OMe-Ph 
5g 4-OMe-Ph 4-OMe-Ph 6g 4-OMe-Ph 4-OMe-Ph 
5h 4-OMe-Ph Me 6h 4-OMe-Ph Me 
5i 3,4,5-(OMe)3-Ph Ph 6i 3,4,5-(OMe)3-Ph Ph 
5j 3,4,5-(OMe)3-Ph 2-OMe-Ph 6j 3,4,5-(OMe)3-Ph 2-OMe-Ph 
5k 3,4,5-(OMe)3-Ph 4-OMe-Ph 6k 3,4,5-(OMe)3-Ph 4-OMe-Ph 
5l 3,4,5-(OMe)3-Ph Me 6l 3,4,5-(OMe)3-Ph Me 
 
 
Alternatively, o-aminoaldehydes 23a-c and 24a-c were reacted with triethyl phosphonoacetate, 
using potassium carbonate as base, allowing the isolation of naphthyridine-8-ones derivatives 
7a-c and 8a-c (Table 2). 
 
Table 2. Naphthyridine-8-one derivatives 7a-c and 8a-c. 
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Compd R Compd R 
7a Ph 8a Ph 
7b 4-OMe-Ph 8b 4-OMe-Ph 
7c 3,4,5-(OMe)3-Ph 8c 3,4,5-(OMe)3-Ph 
 
2.2  Biology 
2.2.1 Spectrophotometric properties 
The essential requirement for a photosensitizer compound is the absorption of UV-Vis light. The 
absorption spectra of compounds were collected in phosphate buffer (20 mM, pH 7.4) and ε 
values were calculated in correspondence of both λmax and λ365 nm. All compounds absorbed UV-Vis 
light with maximum peaks in the UV-A region (300-365 nm), a fundamental feature for a 
photosensitizer (Table 3 and Figure S1).  
 
Table 3. Spectrophotometric properties of selected naphthyridine derivatives of type 5, 6 and 
of naphthyridine-8-one derivatives of type 7, 8. 
 
Compd λ max (nm) ε  max ε 365 (nm) Compd λ max (nm) ε  max ε 365 (nm) 
5a 337 9200 6624 6d 338 10632 2396 
5c 365 8188 8188 6e 325 21760 15384 
5d 310 5200 80 6h 350 10588 7588 
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5f 354 5600 5148 6i 330 15780 11800 
5g 351 6400 6352 6j 327 9976 9084 
5h 302 3520 2316 6l 300 13940 5688 
5i 334 5200 3560 7a 325 8000 924 
5j 352 11600 11172 7b 325 5600 3476 
6b 360 11428 11224 8a 300 21188 176 
The absorption spectra were collected in 20 mM phosphate buffer (PB), pH 7.4 and ε were 
calculated. 
 
2.2.2 Antiproliferative assays 
The antiproliferative activity of the tested compounds was evaluated on a panel of cultured 
human tumor cell lines, representing the most common neoplasms: MCF7 (mammary gland 
adenocarcinoma), HT-29 (colorectal adenocarcinoma) and A375 (malignant melanoma) cells. 
Besides tumor cell lines, the compounds were tested also on the non-tumor cell line MCF10A 
(mammary gland epithelial cells) to assess their selectivity towards malignancies. Moreover, the 
antiproliferative experiments were performed without irradiation by incubating cells with 
compounds for 72 h to evaluate the UV light-independent cytotoxicity.  
Prior to the administration of the compounds, all cell lines were tested for UV phototoxicity to 
achieve the highest compounds’ activation in the absence of cellular cytotoxicity. We set up a 
light dose of 1.5 J/cm2 (corresponding to 5 min of light exposure at 365 nm) at which the amount 
of living cells in the UV-treated and UV-untreated samples was the same. Phototoxicity was 
assessed by MTT test 72 h after UV irradiation in the presence of the compounds. [17,18] 
Phototoxicity was evaluated only for compounds with adequate solubility in DMSO and reported 
as the effective concentration able to kill 50% of the cell population (EC50, Table 4); toxicity in 
the absence of UV exposure was indicated as the cytotoxic concentration able to kill 50% of the 
cell population (CC50).  
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Table 4. Photocytotoxicity EC50 (μM) and cytotoxicity CC50 (μM) in human tumor and non-tumor cell lines measured 72 h post 
administration of selected naphthyridine derivatives of type 5, 6 and naphthyridine-8-one derivatives of type 7, 8. 
 
Compd Human cell  l ines 
 A375 HT-29 MCF7 MCF10A 
 aEC 50 (μM) bCC 50 (μM) cPTI EC 50 (μM) CC 50 (μM) PTI EC 50 (μM) CC 50 (μM) PTI EC 50 (μM) CC 50 (μM) PTI 
5a >50±0 >50±0 n.d. >50±0 >50±0 n.d. >50±0 >50±0 n.d. >50±0 >50±0 n.d. 
5c 10.100±6.920 >50±0 >5 0.099±0.017 >50±0 >508 33.958±12.600 >50±0 >1.5 0.099±0.009 >50±0 >505 
5d >50±0 >50±0 n.d. >50±0 >50±0 n.d. >50±0 >50±0 n.d. >50±0 >50±0 n.d. 
5f 1.094±0.033 >50±0 >46 >50±0 >50±0 n.d. >50±0 >50±0 n.d. >50±0 >50±0 n.d. 
5g 0.875±0.031 >50±0 >57 1.735±0.870 >50±0 >29 >50±0 >50±0 n.d. >50±0 >50±0 n.d. 
5h >50±0 >50±0 n.d. >50±0 >50±0 n.d. >50±0 >50±0 n.d. >50±0 > 50±0 n.d. 
5i >50±0 >50±0 n.d. >50±0 >50±0 n.d. >50±0 >50±0 n.d. >50±0 > 50±0 n.d. 
5j >50±0 >50±0 n.d. >50±0 >50±0 n.d. >50±0 >50±0 n.d. >50±0 > 50±0 n.d. 
6b 0.633±0.081 >50±0 >79 0.197±0.067 >50±0 >254 1.323±0.371 >50±0 >38 1.170±0.099 > 50±0 >43 
6d >50±0 >50±0 n.d. 6.587±0.158 >50±0 >8 >50±0 >50±0 n.d. >50±0 >50±0 n.d. 
6e 0.011±0.009 >50±0 >4545 0.012±0.002 >50±0 >4167 0.010±0.008 >50±0 >5000 0.864± 0.150 >50±0 >58 
6h >50±0 >50±0 n.d. 4.283±0.339 >50±0 >12 >50±0 >50±0 n.d. >50±0 >50±0 n.d. 
6i 1.441±0.600 >50±0 >35 0.620±0.069 >50±0 >81 5.944±0.301 >50±0 >8 4.380±0.099 >50±0 >11 
6j 0.764±0.034 >50±0 >65 0.197±0.020 >50±0 >254 3.529±0.226 >50±0 >14 1.860±0.086 >50±0 >27 
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6l >50±0 >50±0 n.d. >50±0 >50±0 n.d. >50±0 >50±0 n.d. >50±0 >50±0 n.d. 
7a >50±0 >50±0 n.d. >50±0 >50±0 n.d. >50±0 >50±0 n.d. >50±0 >50±0 n.d. 
7b >50±0 >50±0 n.d. >50±0 >50±0 n.d. >50±0 >50±0 n.d. >50±0 >50±0 n.d. 
8a 1.490±0.035 >50±0 >34 >50±0 >50±0 n.d. >50±0 >50±0 n.d. >50±0 >50±0 n.d. 
 
Data are expressed as mean ± SD of at least three different independent experiments. a EC50: Photocytotoxic concentration able 
to kill 50% of the cell population. b CC50: Cytotoxic concentration able to kill 50% of the cell population. c PTI: Phototoxic 
index corresponds to CC50/EC50 ratio; it indicates the effectiveness of the tested compounds upon photoactivation. n.d.: not 
determined. 
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The CC50/EC50 ratio was defined as the photoactivation toxicity index (PTI), i.e. the compounds’ 
ability to kill cells only upon light activation. Moreover, the selectivity index (SI), expressed as 
EC50 of the photoactivated compound in the normal cell line/EC50 of the same compound in the 
cancer cell line, was assessed (Table 5). 
Notably, no cytotoxicity was observed in all the three cell lines by MTT analysis after 72 h of 
incubation with up to 50 μM of the compounds in the absence of UV-light exposure (Table 4). 
Although clear-cut structure-activity relationships (SAR) are not easily assessed, some 
hypotheses can be formulated. Comparing the two classes of compounds, triazole derivatives 5 
and 7 displayed lower cytotoxicity and tumor selectivity, compared to oxazolo-naphthyridines 6 
and naphthyridine-8-ones 8. Triazolo-naphthyridines, of which only three derivatives (5c, 5f 
and 5g) out of the eight could be screened, demonstrated photocytotoxicity with EC50 values at 
the submicromolar/micromolar level (EC50 0.099–33.958 µM); in particular they showed high 
cytotoxicity on the A375 cell line, with EC50 values from submicromolar (5g: EC50 0.875 μM) to 
micromolar (5c: EC50 10.100 μM). The latter derivative 5c was the only one, among the three, 
which proved to be photocytotoxic also against HT-29 (EC50 0.099 μM) and MCF7 cell line (EC50 
33.958 μM) and displayed antiproliferative activity also against the non-tumor cell line 
MCF10A. In contrast, triazolo-naphthyridine-8-ones 7a and 7b were not cytotoxic against the 
three tested tumor cell lines, likely because of their low molar extinction coefficient at 365 nm. 
The best results were obtained with oxazolo-naphthyridines 6: upon irradiation, four out of seven 
tested derivatives were able to induce UV dependent cell death at nanomolar/low micromolar 
concentrations (EC50 0.010–6.587 μM). The most potent derivative was 6e (EC50 0.010–0.012 
μM), which bears a 4-methoxy-phenyl group at position 2 and a phenyl ring at position 8. 
Replacement of the phenyl ring with a methyl group in position 8 caused a drastic loss of activity 
(compare 6e with 6h). Moreover, removal of 4-methoxy-phenyl group and its substitution with a 
phenyl (6b) or 3,4,5-trimethoxyphenyl group (6i, 6j) decreased phototoxicity (6b: EC50 0.197–
1.323 µM, 6i: EC50 0.620–5.944 µM, 6j: EC50 0.197–3.529 µM). In the 3,4,5-trimethoxy series, 
the methyl group in position 8 caused again a complete loss of phototoxicity (6l). 
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Oxazolo-naphthyridine-8-one derivative 8a expressed photocytotoxicity at low micromolar level 
only against the A375 cell line (EC50 1.490 µM).  
Crucial requirements for photosensitizing agents are photocytotoxicity coupled to high ε and SI 
values; the most photocytotoxic compound 6e fulfils these features. It induced UV-dependent 
cell death at nanomolar concentrations, the same order of magnitude of 
pyrrolo[3',2':6,7]cyclohepta[1,2-d]pyrimidines 11, ROS-inducer photosensitizers previously 
reported by us (EC50 0.06–4.96 μM), [17] but in comparison with these, 6e is endowed with 
much higher CC50/EC50 ratio (PTI >5000 in MCF7 cell line) and selectivity for the tumor cell lines 
(SI 72-86) (Table 5). Interestingly 6e is very active on the MCF7 cell line (breast cancer), which 
is one of the most studied human breast cancer cell line and usually not very sensitive to drugs. 
[39,40] When compared to other published PS, such as zinc Phthalocyanine, 6e demonstrated no 
cytotoxicity in the absence of irradiation and much lower EC50 (nanomolar vs micromolar range) 
than phthalocyanine on tumor cell lines (Obata, T (2015) Photodynamic Therapy Using Novel 
Zinc Phthalocyanine Derivatives and a Diode Laser for Superficial Tumors in Experimental 
Animals. Journal of Cancer Therapy, 6, 53-61. http://dx.doi.org/10.4236/jct.2015.61008). 
Moreover, taking into consideration compounds with similar absorption spectra and intracellular 
accumulation, i.e. Chlorine e6 and derivatives, 6e was characterized by a higher cytotoxic effect 
(EC50 in the low nanomolar range vs micromolar-high nanomolar range of chlorine e6 and 
derivatives) and a remarkably higher PTI (>5000 for 6e vs 466.6 of the most active Chlorine e6 
derivative). (J Med Chem. 2011 Nov 10;54(21):7464-76. doi: 10.1021/jm2005139. Epub 2011 
Oct 7.)  These are very promising results, which pave the way to further drug development. 
 
Table 5. SI values of selected naphthyridine derivatives of type 5-6 and of naphthyridine-8-one 
derivatives of type 7-8. 
Compd MCF10A/A37
5 
MCF10A/HT-29 MCF10A/MCF
7 
5a n.d. n.d. n.d. 
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5c 0.009 1.01 0.003 
5d n.d. n.d. n.d. 
5f 46 >1 >1 
5g 57 29 >1 
5h n.d. n.d. n.d. 
5i  n.d. n.d. n.d. 
5j  n.d. n.d. n.d. 
6b 2 6 0.884 
6d n.d. 8 n.d. 
6e 79 72 86 
6h n.d. 12 n.d. 
6i  3 7 0.737 
6j 2 9 0.527 
6l n.d. n.d. n.d. 
7a n.d. n.d. n.d. 
7b n.d. n.d. n.d. 
8a 34 n.d. n.d. 
 
SI: selectivity index corresponds to EC50 of photoactivated compound in the normal cell line/EC50 
of the same compound in the cancer cell line and indicates the degree of tumor selectivity of the 
photoactivated compounds.  
 
2.2.3 Cell cytotoxicity localization: cytosolic ROS induction is required for 
naphthyridines-induced cell death 
To explore the cellular mechanisms underlying phototoxicity of the tested compounds, we chose 
the most active and selective compound (6e) for further biological assays. To assess the cellular 
compartments affected by the compound, we administrated 6e to MCF7 cells and monitored its 
localization over 1 h time (Figure 1). 
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Figure 1. Subcellular localization of derivative 6e in MCF7 cells. After 10 min (A) the 
compound (2 μM, blue signal) distributes within the cytoplasm, the same localization was 
recorded after 30 min (B) and 1 h (C) post administration. Cellular nuclei were counterstained in 
red. 
 
Thanks to its fluorescent properties, 6e was detected using a confocal microscope (λex 405 nm, λem 
415-460 nm) (Figure S2). As depicted in Figure 1, 6e rapidly entered MCF7 cells and widely 
distributed into the whole cytoplasm, with some punctate accumulation visible within 10 min of 
exposure (Figure 1, panel A, 10 min, blue signal). Thirty min - 1 h post administration (Figure 1, 
panels B and C), 6e subcellular localization remained in the cytoplasm: areas of more intense 
signal were still visible but randomly distributed, thus independent of intra-organelle 
accumulation, as reported for other photosensitizer. [41] No nuclear signal was ever detected. 
Taken together, these results led us to investigate a cytosolic DNA-unrelated mechanism of 
cellular toxicity.  
 
2.2.4 Spectroscopic and kinetic characterization of the triplet excited state of 
6e 
To clarify the origin of the photocytotoxicity, we decided to provide a full characterization of the 
newly synthesized naphthyridine derivative 6e as singlet oxygen sensitizer. Therefore, we 
preliminarily detected its lowest triplet-excited state (T1) defining spectroscopic and kinetic 
features. In fact, it is well known that the population of a triplet excited state and its lifetime are 
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both directly correlated to the efficiency of the generation of singlet oxygen. We set out to 
compare these issues for 6e, the most photocytotoxic naphthyridine, with 5h, the least 
photocytotoxic one. For solubility reasons, it was not possible to compare the two naphthyridines 
in aqueous media. Consequently, 6e and 5h were irradiated in acetonitrile by nanosecond laser 
flash photolysis (LFP), using a Nd:YAG laser, operating at 355 nm. Upon laser excitation at 355 
nm, we recorded the transient absorption spectra in the range of 350-700 nm for both 6e and 5h 
(Figure 2a and 2b, respectively).  
 
Figure 2. Time-resolved difference absorption spectra (ΔA) flashing argon-purged acetonitrile 
solutions of 6e (1 x 10-4 M) (a) and 5h (5 x 10-4 M) (b), at 355 nm.  
 
A maximum of absorbance was recorded for both naphthyridine 6e (λmax 650, Figure 2a) and 5h 
(λmax 530 nm, Figure 2b). The transient absorption profiles decayed monoexponentially in air-
equilibrated solutions with an identical lifetime of τ = 0.2 µs. In argon-saturated solutions, the 
lifetime of the transient specie from 6e became bi-exponential (τ1 = 4.7 µs, 18%; τ2 = 18 µs, 
82%, Figure 3). Such an oxygen-dependent lifetime indicates that at the LFP pulse end we are 
very likely observing the triplet-state absorption of 6e. A similar behaviour was also recorded 
for 5h. The intensity of the signal assigned to the triplet excited states (T1) of 6e monitored at 
650 nm (A = 4.3 X 10-2) was approximately 3 times more intense than that assigned to the T1 of 
5h recorded at 530 nm (A = 1.4 X 10-2). Assuming that the molar extinction coefficients of T1 are 
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similar, all the data collected suggest that 5h does not efficiently generate a triplet-excited state. 
Conversely, 6e exhibiting T1 with an exceptionally long 18.0 µs lifetime and a high molar 
absorptivity (29781±180 M-1cm-1 at λmax 315 nm) may act as an interesting singlet oxygen 
sensitizer for biological applications.  
 
Figure 3. Triplet decay trace of 6e monitored at 630 nm in neat acetonitrile under argon 
saturated condition.  
 
2.2.5 Generation and trapping of 1O 2 by 9,10-anthracenedipropionic acid in 
aqueous acetonitrile 
To further evaluate the efficiency of 6e and 5h as 1O2 photosensitizer, we investigated the photo-
oxidation of 9,10-anthracenedipropionic acid (ADPA), a water-soluble and efficient 1O2 trap, 
forming a colourless endoperoxide via a [4 + 2] Diels-Alder cycloaddition. The photo-oxidation 
of ADPA by 1O2 was followed monitoring the absorption at 400 nm, which indicates the 
consumption of the ADPA anthracene chromophore. [42] The experiments were carried out in 
aqueous acetonitrile (acetonitrile: water = 3:2). We did not use higher water content to avoid 
solubility issues for both 6e and 5h. The continuous photo-bleaching of the anthracene 
absorption in the presence of both 6e and 5h, monitored for 1 h at 315 nm excitation 
wavelength, indicated the photogeneration of 1O2 (Figures S3 and S4). By-product formation was 
 19 
not detected during irradiation both by UV absorption and HPLC analysis. We did not record any 
decrease in the anthracene absorbance in the solutions without the sensitizer. We measured by 
ferrioxalate actinometry the efficiency of the ADPA consumption (ΦR-315: quantum yield) 
irradiating at 315 nm both naphthyridines. Surprisingly, the quantum yields for 6e and 5h were 
fairly low and very similar with ΦR-315 = 0.020 ± 0.002. The quantum yield for ADPA consumption 
using 6e as 1O2 sensitizer measured irradiating at 360 nm (ΦR- 360) was slightly higher (ΦR- 360 = 0.025 
± 0.003). Buffering conditions in the same solvent did not substantially affect the quantum yield. 
We were not able to reliably measure ΦR- 360 of 5h irradiated at 360 nm, as its absorbance was 
negligible at that wavelength (Figure 4). 
 
 
Figure 4. Absorbance comparison of 6e (10-4 M) and 5h (10-4 M) in acetonitrile: water = 3:2 
solutions. 
 
These data suggest that both 6e and 5h are capable to act as 1O2 photosensitizers with 
comparable efficiency at 315 nm. The different photocytotoxicity described above, has to be 
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ascribed to their differential optical properties, as 6e exhibits much higher absorptivity at longer 
wavelength (with a tail above 400 nm) than 5h (Figure 4). 
2.2.5 Production of reactive oxygen species (ROS) upon UV irradiation 
Generation of Reactive Oxygen Species (ROS) in cancer cells was next evaluated for compounds 
6e and 5h. We employed the cell-permeant dichlorofluorescein (DCF) probe, which is converted 
to a highly fluorescent dye by ROS. Fluorescence in the presence/absence of UV irradiation 
(λ~365 nm) was quantitatively evaluated in cells treated with the selected compounds; non-
treated cells were used as negative controls. Cells treated with phorbol-12-myristate-13-acetate 
(PMA) and light activated were used as a positive control of intracellular ROS generation. 
[43,44] After 2 h from photoactivation, increasing concentrations of 6e (0.5-2 µM) showed a 
steady increase in fluorescence, which reached 227% of the untreated control (100%) at the 
highest concentration (Figure 5).  
 
 
Figure 5. ROS production upon photoactivation of 6e and 5h. The increase in intracellular ROS 
levels was determined by a DCF-probe and was calculated as fluorescence increase compared to 
untreated irradiated controls. Assays were performed on non-treated (control), 6e, 5h and PMA 
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treated cells, after 2 h from light exposure, in minimal medium (no scavenger) and in medium 
containing an antioxidant compound at various concentration (i.e. N-acetylcysteine, NAC 200 
nM and 500 nM). Results from three independent experiments are shown. 
 
Conversely, treatment with 5h or the administration of compounds without UV exposure did not 
modify control levels of fluorescence (Figure S5). The positive control sample (PMA, 400 nM) 
reached 120% of the untreated control 2 h after photoactivation (Figure 5). These data indicate 
that generation of ROS in cells by 6e is massive and rises more rapidly than that mediated by the 
ROS inductor PMA. Moreover, compared to other ROS-inducer photosensitizers previously 
published by us, [17,18] 6e resulted more potent and active at much lower concentration. To 
support the relevance of 6e-induced ROS, we pre-incubated cells with the ROS scavenger N-
acetylcysteine (NAC, 200-500 nM) and observed that NAC significantly reduced the generation 
of reactive species, in a dose dependent manner (Figure 5). [45] These results indicate that 6e 
promptly and massively produces ROS in cells.  Statistical analysis (Two tailed Student’s t-test,  
P-value < 0.01) indicated that ROS levels measured in 6e-treated cells were significant, while 
5h-treated cells were not significantly different from control samples. NAC-induced ROS 
depletion was significant in all samples.  
 
2.2.6 Cytotoxicity mechanisms: cell death pathways 
As production of copious amounts of ROS can trigger cell death by several different pathways, 
we next examined which mechanism (apoptosis or necrosis) of cell death was induced by 6e.  
The first feature that was taken into consideration was the distribution of MCF-7 cells in the cell 
cycle phases 24 h after administration of compounds 6e and 5h. The exposure of MCF7 cells to 
6e upon UV-activation did not alter the distribution of the cells in the different phases of the cell 
cycle (Figure S6), as assessed by flow cytometry analysis (PI staining, living cell population). 
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Statistical analysis also confirmed that cell population distribution in treated cells was not 
significantly altered in treated samples. This result suggested that cell death that could be related 
to a rapid and harsh intracellular damage rather than block during the normal cell cycle. To shed 
light on this aspect, a double staining (PI and Annexin V FITC) flow cytofluorimetry analysis 
was performed to discriminate the early and late stages of apoptosis. The presence of necrosis 
was also evaluated. MCF7 cells were treated with 6e and 5h at increasing concentrations (EC25, 
EC50 and EC75 or EC50 respectively) and the whole cell population was analyzed. [46] At 4 h post 
photoactivation, 44-60% (depending on the drug concentration) of cells treated with compound 
6e showed features of non-living cells and were classified as apoptotic (34-50%), or necrotic 
(10%) cells (Figure 6). 
 
 
Figure 6. Cell population analysis. MCF7 cells were treated with 6e at various concentrations 
(EC25, EC50 and EC75) and 5h at EC50 and double stained with 7AAD and PE Annexin V 4 h after 
photoirradiation. Reported values represent the mean of three independent experiments. 
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In contrast, control cells and cells treated with 5h were characterized by a large fraction of living 
cells (95% and 90%, respectively) and displayed only low amounts of apoptotic and necrotic 
cells (4% and 7%, respectively). These results evidenced that the administration and subsequent 
photoactivation of active compound 6e caused a massive and very rapid cell death in tumor cells. 
Student T-test (two tailed, P<0.01) was performed and assessed that data obtained for 6e-treated 
cells were statistically significant, while 5h-treated cells were comparable to control non-treated 
cells.  As compared to other photoactivated compounds, oxazolo-derivatives pushed the majority 
of cell population into an irreversible apoptotic process in a shorter time lapse. [17,18] The 
triggering of apoptosis is a favourable feature for a chemotherapic drug, since, unlike necrosis, 
the apoptotic process does not cause an inflammatory reaction.  
2.2.7 Cytotoxicity mechanisms: mitochondrial and lysosomal-dependent ROS 
response 
Different intracellular signaling pathways, including mitochondrial dysfunction and lysosome 
activation, trigger and carry on the apoptotic process; we thus proceeded examining both 
mitochondrial and lysosomal involvement in 6e-treated photoactivated cells. The induction of 
mitochondrial dysfunction was assessed with a mitochondrial membrane fluorescent probe, 
which allows to monitor morphology and mitochondria distribution within the cells. Untreated 
and treated cells with/without UV irradiation, were evaluated by confocal imaging. Control cells 
(untreated and non-irradiated) displayed the typical pattern of mitochondrial organization 
reported for the MCF7 cell line, characterized by a more fragmented network compared to non-
metastatic breast cancer cells (Figure 7, panel A). [47-49] 
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Figure 7. Mitochondrial morphology modifications induced by light-activated 6e and 5h. 
Mitochondrial membranes were visualized with a membrane potential-specific red fluorescent 
probe. A: non-treated and non-irradiated cells; B: non-treated and irradiated cells and C: PMA-
treated cells (400 nM). D: 6e, 2 µM, 20 min after UV exposure; E: 6e, 2 µM, 2 h after UV 
exposure; F: 5h, 2 µM, 2 h after UV exposure. Well-defined mitochondrial network morphology 
was stained in non-treated cells, irradiated and non-irradiated, as well as in 5h treated and 
irradiated cells (A, B and C). Cells treated with 6e, following photoactivation, underwent 
significant mitochondrial network impairment and organelles swelling, already visible after 20 
min (D and E). PMA was used as ROS-inducer positive control: a condensed mitochondrial 
network was visible 6 h post treatment (F). 
 
Cells irradiated in the absence of ROS-generating compounds as well as cells treated with the 
compounds and non-irradiated were characterized by a similar mitochondrial network (Figure 7, 
panel B and Figure S7, panels B-C). Notably, UV-activated 6e caused an early remodeling of 
mitochondrial network, characterized by perinuclear clustering (Figure 7, panel D), followed by 
organelles fusion and mild swelling (Figure 7, panel E). This effect burst soon after UV exposure 
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(20 min) and was even more intense 2 h after compound photoactivation. Conversely, 5h in the 
same conditions did not induce any detectable mitochondrial perturbation (Figure 7, panel F). 
Treatment with PMA induced moderate mitochondria fusion after 6 h of treatment (Figure 7, 
panel C). 
To further characterize the UV-activated 6e induced cell death, the lysosomal involvement in the 
apoptotic process was also evaluated. A fluorescent probe able to stain acidic subcellular 
compartments, such as lysosomes and endosomes, was used. Cells treated with 6e that also 
underwent UV irradiation showed considerable lysosomes activation, visible as bright green dots 
within the cytoplasm. Lysosomes activation was detectable 20 min after compound activation 
(green signal, Figure 8, panels D-E).  
 
 
Figure 8. Lysosomes activation induced by UV-activated 6e and 5h. Lysosomes were visualized 
with a green fluorescent probe. A: non-treated and non-irradiated cells; B: non-treated and 
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irradiated cells and C: PMA-treated cells (400 nM). D: 6e, 2 µM, 20 min after UV exposure; E: 
6e, 2 µM, 2 h after UV exposure; F: 5h, 2 µM, 2 h after UV exposure. Non-treated MCF7 cells, 
irradiated and non-irradiated, showed none or minimal lysosome activation (A and B), as well as 
cells treated with 5h. UV-activated 6e displays a punctate distributed lysosomal activation after 
20 min. After 2 h considerable lysosomal membrane depolarization was obtained, but lysosomes 
retain their shape and distribution within the cytoplasm. 
 
The weak fluorescence detected in the cytoplasm indicated lysosomal membrane 
permeabilization, likely linked to the ROS outburst. [50,51] Two h after treatment, the probe 
signal decreased, although clear perinuclear punctate staining was still visible, indicating an 
augmented lysosomal membrane permeabilization and an ongoing late apoptotic phase. [51] 
PMA treatment (400 nM, 6 h after treatment) induced a minimal lysosome signal (Figure 8, 
panel C). In contrast, cell treatment with 5h in the presence/absence of UV irradiation did not 
induce lysosome activation (Figure 8, panel F, Figure S7, panel F). Similarly, non-treated control 
cells, with and without UV irradiation displayed negligible fluorescent signal (Figure 8, panels 
A-B, Figure S7, panels D-E).  
Altogether, these studies demonstrated that ROS generation was necessary for naphthyridines-
mediated cytotoxicity. The antiproliferative effect was triggered by a burst of ROS levels that 
promptly induced an unquenchable apoptotic process in tumor cells, featured by lysosomal 
involvement.  
 
3. Conclusions  
In our continuing efforts aimed at the study of heterocyclic scaffold as precursors of new 
potential photosensitizing agents with improved properties, [1,2,3]triazolo[4,5-
h][1,6]naphthyridines 5, [1,2,3]triazolo[4,5-h][1,6]naphthyridin-8-ones 7, [1,3]oxazolo[5,4-
h][1,6]naphthyridines 6, and [1,3]oxazolo[5,4-h][1,6]naphthyridin-8-ones 8 were prepared in 
moderate to good yield (40-65%) through a multistep procedure, in order to investigate their 
photochemotherapeutic activities. Phototoxicity against three tumor cell lines (MCF7, A375 and 
 27 
HT-29) was assessed; upon irradiation, oxazolo-naphthyridines of type 6, expressed growth 
inhibitory activity at nanomolar/low micromolar concentrations (EC50 0.010–6.587 µM). In 
particular, the most potent derivative 6e was very active against MCF7 cell line, which is 
usually not very sensitive to drugs, and exhibited high selectivity (SI=72-86) and photocytoxicity 
indexes (PTI >5000). Photocytotoxicity of oxazolo-naphthyridine 6e is strictly connected to its 
optical properties as it exhibited high molar absorptivity (29781±180 M-1cm-1 at λmax 315 nm), with 
a tail above 400 nm. Laser flash photolysis studies revealed that derivative 6e efficiently 
generated a triplet-excited state with an exceptionally long 18.0 µs lifetime. 
Cellular mechanisms of phototoxicity indicated that derivative 6e is distributed in the cytoplasm, 
thus exerting a cytosolic DNA-unrelated mechanism of cellular toxicity. Upon UV-activation, 6e 
promptly and massively produced ROS in cells even more rapidly than the ROS inducer PMA. 
Thus the antiproliferative effect was triggered by a burst of ROS levels that immediately induced 
an unquenchable apoptotic process selectively in tumor cells, with both lysosomal and 
mitochondrial involvement. These findings are of great relevance since indicate that 6e may act 
as a very promising singlet oxygen sensitizer for biological applications, paving the way to 
further drug development. 
 
 
4. Experimental 
4.1 Chemistry 
All melting points were taken on a Büchi melting point M-560 apparatus. IR spectra were 
determined in bromoform with a Shimadzu FT/IR 8400S spectrophotometer. 1H and 13C NMR 
spectra were measured at 200 and 50.0 MHz, respectively, in DMSO-d6 or CDCl3 solution, using 
a Bruker Avance II series 200 MHz spectrometer. Column chromatography was performed with 
Merk silica gel 230-400 mesh ASTM or with Büchi Sepacor chromatography module (prepacked 
cartridge system). Elemental analyses (C, H, N) were within ± 0.4% of theoretical values and 
were performed with a VARIO EL III elemental analyzer. The purity of all the tested compounds 
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was >95%, determined by HPLC (Agilent 1100 series). In particular, (NH4)2HPO4 0.4 
M/acetonitrile 68:32 v/v was used as eluent, with a flow rate of 1 mL/min, filtered on a cellulose 
regenerated filter, cut off 0.2 μm, and samples injected in a C18 Gemini HPLC column. The 
purity was calculated by using a calibration curve obtained for serially diluted concentrations of 
compounds (Kmax = 254 nm) in the eluent and expressed as the amount of intact molecules per unit 
mass. 
General procedures, analytical and spectroscopic data for compounds 13a-c, were previously 
reported. [52,53] 
 
4.1.1  General Procedure for the Synthesis of 5-Amino-1-substituted-1H-1,2,3-
triazole-4-carbonitrile derivatives (17a-c)   
To a solution of sodium etoxide (0.29 g, 4.30 mmol) in anhydrous ethanol (10 mL), 
malononitrile 14 (0.27 g, 4.08 mmol) was added and the reaction was stirred at room 
temperature for 15 min. Then the solution of the suitable azido derivative 13a-c (3.40 mmol) in 
anhydrous ethanol (10 mL) was added at 0°C and the reaction mixture was stirred at room 
temperature for 12 h. The solvent was removed under reduced pressure and the crude product 
was purified by chromatography (DCM/AcOEt 95/5) 
4.1.1.1  5-Amino-1-phenyl-1H-1,2,3-triazole-4-carbonitrile (17a)   
Light brown; yield: 60%; mp: 125.5-126.6 oC; IR cm-1: 3380, 3330 (NH2), 2249 (CN); 1H NMR 
(200 MHz, CDCl3) δ: 5.02 (2H, bs, NH2), 7.50-7.63 (5H, m, Ar); 13C NMR (50 MHz, CDCl3) δ: 
103.9 (s), 112.4 (s), 124.4 (2 x d), 130.4 (d), 130.5 (2 x d), 136.7 (s), 146.6 (s). Anal. Calcd for 
C9H7N5: C, 58.37; H, 3.81; N, 37.82. Found: C, 58.15; H, 3.92; N, 37.74. 
 
4.1.1.2  5-Amino-1-(4-methoxyphenyl)-1H-1,2,3-triazole-4-carbonitrile (17b)  
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Light brown; yield: 70%; mp: 189.5-190.0 oC; IR cm-1: 3347, 3290 (NH2), 2234 (CN); 1H NMR 
(200 MHz, DMSO-d6) δ: 3.84 (3H, s, CH3O), 7.02 (2H, bs, NH2), 7.14 (2H, d, J = 10.0 Hz, H2' and 
H6'), 7.23 (2H, d, J = 10.0 Hz, H3' and H5'); 13C NMR (50 MHz, DMSO-d6) δ: 55.6 (q), 100.9 (s), 
113.5 (s), 114.9 (2 x d), 126.6 (s), 126.8 (2 x d), 148.0 (s), 160.0 (s). Anal. Calcd for C10H9N5O: C, 
55.81; H, 4.22; N, 32.54. Found: C, 55.93; H, 4.13; N, 32.45. 
 
4.1.1.3  5-Amino-1-(3,4,5-trimethoxyphenyl)-1H-1,2,3-triazole-4-carbonitrile 
(17c)  
Light brown; yield: 60%; mp: 173.3-174.0 oC; IR cm-1: 3405, 3353 (NH2), 2223 (CN); 1H NMR 
(200 MHz, CDCl3) δ: 3.90 (9H, s, 3 x CH3O), 4.94 (2H, bs, NH2), 6.70 (2H, s, H2' and H6'); 13C 
NMR (50 MHz, CDCl3) δ: 56.5 (2 x q), 61.1 (q), 100.0 (s), 102.1 (2 x d), 112.3 (s), 128.9 (s), 
139.3 (s), 146.6 (s), 154.3 (2 x s). Anal. Calcd for C12H13N5O3: C, 52.36; H, 4.76; N, 25.44. Found: 
C, 52.48; H, 4.53; N, 25.35. 
 
4.1.2  General Procedure for the Synthesis of 5-Amino-2-
substituted[1,3]oxazole-4-carbonitrile derivatives (18a-c)  
These compounds were synthesized according to the previously described procedure. [38] To a 
stirred solution of 1.7 g of aminomalononitrile tosylate 16 (4.6 mmol) in 1-methyl-2-
pyrrolidinone (12 mL, 117.0 mmol) the suitable benzoyl chloride 15a-c (5.1 mmol) was added. 
The reaction mixture was stirred at room temperature for 12 hours and then, diluted with 100 mL 
of a 1:1 solution of ethyl acetate: ethyl ether, washed with water (2x100 mL), and a 10% 
saturated solution of sodium hydrogen carbonate (2x100 mL). The organic layer was dried over 
sodium sulphate and the solvent removed under reduced pressure.  
4.1.2.1  5-Amino-2-phenyl[1,3]oxazole-4-carbonitrile derivatives (18a)   
This compound was obtained in 79% yield. Analytical and spectroscopic data are in accordance 
to those reported in literature. [54]  
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4.1.2.2  5-Amino-2-(4-methoxyphenyl)[1,3]oxazole-4-carbonitrile (18b) 
This compound was obtained in 51% yield. Analytical and spectroscopic data are in accordance 
to those reported in literature. [55]  
4.1.2.3  5-Amino-2-(3,4,5-trimethoxyphenyl)-[1,3]oxazole-4-carbonitrile (18c)  
White solid; yield: 58%; mp: 241.3-242.6 oC; IR cm-1: 3328, 3216 (NH2), 2221 (CN); 1H NMR 
(200 MHz, DMSO-d6) δ: 3.71 (3H, s, CH3O), 3.84 (6H, s, CH3Ox2), 7.02 (2H, s, H2' and H6'), 8.01 
(2H, s, NH2); 13C NMR (50 MHz, DMSO-d6) δ: 55.8 (2 x q), 60.1 (q), 84.0 (s), 102.1 (2 x d), 
115.3 (s), 121.3 (s), 138.9 (s), 149.2 (s), 153.2 (2 x s), 162.2 (s). Anal. Calcd. for C13H13N3O4: C, 
56.72; H, 4.76; N, 15.27. Found: C, 56.53; H, 4.60; N, 15.45. 
 
4.1.3  General Procedure for the Synthesis of Ethyl 7-amino-5-methyl-3-
substituted-3H-[1,2,3]triazolo[4,5-b]pyridine-6-carboxylate  derivatives (19a-c) 
and Ethyl 7-amino-5-methyl-2- substituted[1,3]oxazolo[5,4-b]pyridine-6-
carboxylate derivatives (20a-c)  
These compounds were synthesized according to the procedure reported in [56], slightly 
modified by us. To a mixture of ethyl acetoacetate (0.20 mL, 1.54 mmol) and 5-amino-1-
substituted-1H-1,2,3-triazole-4-carbonitriles 17a-c (1.27 mmol) or 5-amino-2-
substituted[1,3]oxazole-4-carbonitriles 18a-c (1.27 mmol) in anhydrous toluene (50 mL), 
stannic chloride (0.18 mL, 1.54 mmol) was slowly added at 0oC. The mixture was refluxed for 2 
hours using a Dean-Stark trap. After cooling 0.07 mmol of stannic chloride were added and the 
reaction mixture was further refluxed for 2 hours. After the complete depletion of the starting 
material, sodium hydroxide 5M solution was added to pH 10; the reaction mixture was extracted 
with AcOEt (3x50 mL). The organic layer was dried over sodium sulphate and the solvent 
removed under reduced pressure. The crude product was purified by chromatography 
(DCM/AcOEt 9/1). 
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4.1.3.1  Ethyl 7-amino-5-methyl-3-phenyl-3H-[1,2,3]triazolo[4,5-b]pyridine-6-
carboxylate (19a)  
White solid; yield: 45%; mp: 164.8 - 165.1 oC; IR cm-1: 3496, 3359 (NH2), 1680 (CO); 1H NMR 
(200 MHz, CDCl3) δ: 1.44 (3H, t, J = 8.0 Hz, CH3), 2.84 (3H, s, CH3), 4.43 (2H, q, J = 8.0 Hz, 
CH2), 7.32 (2H, s, NH2), 7.43 (1H, t, J = 7.2 Hz, H4’), 7.57 (t, 2H, J = 7.2 Hz, H3’ and H5’), 8.28 (d, 
2H, J = 7.2 Hz, H2’ and H6’); 13C NMR (50 MHz, CDCl3) δ: 14.3 (q), 28.5 (q), 61.1 (t), 102.8 (s), 
121.4 (2 x d), 128.0 (s), 128.1 (d), 129.4 (2 x d), 136.6 (s), 145.2 (s), 149.5 (s), 164.3 (s), 168.6 
(s). Anal. Calcd for C15H15N5O2: C, 60.60; H, 5.09; N, 23.56. Found: C, 60.71; H, 4.89; N, 23.42. 
 
4.1.3.2  Ethyl 7-amino-3-(4-methoxyphenyl)-5-methyl-3H-[1,2,3]triazolo[4,5-
b]pyridine-6-carboxylate (19b)  
White solid; yield: 62%; mp: 179.1-180.0 oC; IR cm-1: 3448, 3333 (NH2), 1688 (CO); 1H NMR 
(200 MHz, CDCl3) δ: 1.44 (3H, t, J=8.0 Hz, CH3), 2.83 (3H, s, CH3), 3.88 (3H, s, CH3O), 4.46 
(2H, q, J = 8.0 Hz, CH2), 7.08 (2H, d, J = 8.0 Hz, H2' and H6'), 7.28 (2H, bs, NH2), 8.12 (2H, d, J = 
8.0 Hz, H3' and H5'); 13C NMR (50 MHz, CDCl3) δ: 14.3 (q), 28.5 (q), 55.6 (q), 61.0 (t), 102.7 (s), 
114.6 (2 x d), 123.2 (2 x d), 127.8 (s), 129.7 (s), 145.0 (s), 149.4 (s), 159.3 (s), 164.2 (s), 168.7 
(s). Anal. Calcd for C16H17N5O3: C, 58.71; H, 5.23; N, 21.39. Found: C, 58.54; H, 5.30; N, 21.48. 
 
4.1.3.3  Ethyl 7-amino-5-methyl-3-(3,4,5-trimethoxyphenyl)-3H-
[1,2,3]triazolo[4,5-b]pyridine-6-carboxylate (19c)  
White solid; yield: 50%; mp: 192.9-193.7 oC; IR cm-1: 3455, 3398 (NH2), 1680 (CO); 1H NMR 
(200 MHz, DMSO-d6) δ: 1.34 (3H, t, J = 8.2 Hz, CH3), 2.66 (3H, s, CH3), 3.74 (3H, s, CH3O), 
3.88 (6H, s, CH3Ox2), 4.35 (2H, q, J = 8.2 Hz, CH2), 7.56 (2H, s, H2' and H6'), 8.06 (2H, s, NH2); 13C 
NMR (50 MHz, DMSO-d6) δ: 14.0 (q), 27.1 (q), 56.1 (2 x q), 60.2 (q), 61.0 (t), 99.2 (2 x d), 99.5 
(s), 99.6 (s), 103.4 (s), 131.8 (s), 114.9 (s), 148.1 (s), 153.2 (2 x s), 162.2 (s), 167.4 (s). Anal. 
Calcd for C18H21N5O5: C, 55.81; H, 5.46; N, 18.08. Found: C, 55.94; H, 5.32; N, 17.94. 
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4.1.3.4 Ethyl 7-amino-5-methyl-2-phenyl[1,3]oxazolo[5,4-b]pyridine-6-carboxylate (20a) 
This compound was obtained in 45% yield. Analytical and spectroscopic data are in accordance 
to those reported in literature. [56]  
 
4.1.3.5  Ethyl 7-amino-2-(4-methoxyphenyl)-5-methyl[1,3]oxazolo[5,4-
b]pyridine-6-carboxylate (20b) 
White solid; yield: 65%; mp: 173.2-173.5 oC; IR cm-1: 3415, 3321 (NH2), 1670 (CO); 1H NMR 
(200 MHz, CDCl3) δ: 1.44 (3H, t, J = 7.2 Hz, CH3), 2.79 (3H, s, CH3), 3.89 (3H, s, CH3O), 4.42 
(2H, q, J = 7.2 Hz, CH2), 6.61 (2H, s, NH2), 7.01 (2H, d, J = 8.6 Hz, H3' and H5'), 8.12 (2H, d, J = 
8.6 Hz, H2' and H6'); 13C NMR (50 MHz, CDCl3) δ: 14.3 (q), 27.4 (q), 55.4 (q), 61.0 (t), 105.9 (s), 
114.4 (2 x d), 119.3 (s), 119.4 (s), 128.9 (2 x d), 148.6 (s), 158.6 (s), 159.4 (s), 159.9 (s), 162.2 
(s), 168.6 (s). Anal. Calcd. for C17H17N3O4: C, 62.38; H, 5.23; N, 12.84. Found: C, 62.20; H, 5.15; 
N, 12.97. 
 
4.1.3.6  Ethyl 7-amino-5-methyl-2-(3,4,5-trimethoxyphenyl)[1,3]oxazolo[5,4-
b]pyridine-6-carboxylate (20c) 
White solid; yield: 45%; mp: 183.4-185 oC; IR cm-1: 3450, 3350 (NH2), 1674 (CO); 1H NMR (200 
MHz, DMSO-d6) δ: 1.45 (3H, t, J = 7.2 Hz, CH3), 2.79 (3H, s, CH3), 3.93 (3H, s, CH3O), 3.97 
(6H, s, 2 x CH3O), 4.43 (2H, q, J = 7.2 Hz, CH2), 6.66 (2H, s, NH2), 7.44 (2H, s, H2' and H6'); 13C 
NMR (50 MHz, DMSO-d6) δ: 14.3 (q), 27.5 (q), 56.3 (2 x q), 61.0 (q), 61.1 (t), 104.2 (2 x d), 
106.0 (s), 119.2 (s), 121.9 (s), 140.9 (s), 148.9 (s), 153.6 (2 x s), 159.1 (s), 159.4 (s), 159.5 (s), 
168.6 (s). Anal. Calcd. for C19H21N3O6: C, 58.91; H, 5.46; N, 10.85. Found: C, 58.80; H, 5.32; N, 
11.01. 
 
4.1.4  General Procedure for the Synthesis of (7-amino-5-methyl-3-substituted-
3H-[1,2,3]triazolo[4,5-b]pyridin-6-yl)methanol  derivatives (21a-c) and (7-
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amino-5-methyl-2- substituted[1,3]oxazolo[5,4-b]pyridin-6-yl)methanol 
derivatives (22a-c)  
To a suspension of lithium aluminium hydride (0.07 g, 2.11 mmol) in anhydrous tetrahydrofuran 
(10 mL), the suitable ethyl 7-amino-5-methyl-3-substituted-3H-[1,2,3]triazolo[4,5-b]pyridine-6-
carboxylate 19a-c (0.64 mmol) or ethyl 7-amino-5-methyl-2-substituted-[1,3]oxazolo[5,4-
b]pyridine-6-carboxylate 20a-c (0.64 mmol) was added at 0° C and the resulting suspension 
was stirred at room  temperature for 12 h. The reaction mixture was poured onto crushed ice. The 
precipitate was filtered, dried and washed with diethyl ether. 
 
4.1.4.1  (7-Amino-5-methyl-3-phenyl-3H-[1,2,3]triazolo[4,5-b]pyridin-6-
yl)methanol (21a)  
White solid; yield: 92%; mp: >350oC; IR cm-1: 3460 (OH), 3421, 3335 (NH2); 1H NMR (200 
MHz, DMSO-d6) δ: 2.58 (3H, s, CH3), 4.61 (2H, d, J = 5.2 Hz, CH2), 4.84 (1H, t, J = 5.2 Hz, OH), 
7.12 (2H, s, NH2), 7.48 (1H, t, J = 7.3 Hz, H4'), 7.65 (2H, t, J = 7.3 Hz, H3' and H5'), 8.26 (2H, d, J = 
7.3 Hz, H2' and H6'); 13C NMR (50 MHz, DMSO-d6) δ: 23.4 (q), 55.5 (t), 111.8 (s), 120.8 (2 x d), 
127.6 (s), 127.9 (2 x d), 129.5 (d), 136.6 (s), 144.6 (s), 145.8 (s), 160.1 (s). Anal. Calcd for 
C13H13N5O: C, 61.17; H, 5.13; N, 27.43. Found: C, 61.23; H, 5.01; N, 27.54. 
4.1.4.2  (7-amino-3-(4-methoxyphenyl)-5-methyl-3H-[1,2,3]triazolo[4,5-
b]pyridin-6-yl)methanol (21b)  
White solid; yield: 58%; mp: >350oC; IR cm-1: 3439 (OH), 3347, 3238 (NH2); 1H NMR (200 
MHz, DMSO-d6) δ: 2.56 (3H, s, CH3), 3.85 (3H, s, CH3O), 4.60 (2H, d, J = 5.1 Hz, CH2), 4.82 
(1H, t, J=5.1 Hz, OH), 7.07 (2H, s, NH2), 7.19 (2H, d, J = 7.1 Hz, H2' and H6'), 8.09 (2H, d, J = 7.1 
Hz, H3' and H5'); 13C NMR (50 MHz, DMSO-d6) δ: 23.4 (q), 55.4 (q), 55.5 (t), 111.6 (s), 114.5 (2 x 
d), 122.7 (2 x d), 127.8 (s), 129.6 (s), 144.4 (s), 145.7 (s), 158.5 (s), 159.9 (s). Anal. Calcd for 
C14H15N5O2: C, 58.94; H, 5.30; N, 24.55. Found: C, 58.83; H, 5.42; N, 24.63. 
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4.1.4.3  (7-amino-5-methyl-3-(3,4,5-trimethoxyphenyl)-3H-[1,2,3]triazolo[4,5-
b]pyridin-6-yl)methanol (21c)  
White solid; yield: 88%; mp: >350oC; IR cm-1: 3513 (OH), 3349, 3341 (NH2); 1H NMR (200 MHz, 
DMSO-d6) δ: 2.58 (3H, s, CH3), 3.74 (3H, s, CH3O), 3.89 (6H, s, 2 x CH3O), 4.60 (2H, d, J = 4.8 
Hz, CH2), 4.83 (1H, t, J = 4.8 Hz, OH), 7.13 (2H, s, NH2) 7.66 (2H, s, H2' and H6'); 13C NMR (50 
MHz, DMSO-d6) δ: 23.6 (q), 55.4 (t), 56.0 (2 x q), 60.2 (q), 98.4 (2 x d), 111.8 (s), 128.0 (s), 
132.5 (s), 136.5 (s), 144.5 (s), 145.8 (s), 159.2 (2 x s), 159.9 (s). Anal. Calcd for C16H19N5O4: C, 
55.64; H, 5.55; N, 20.28. Found: C, 55.77; H, 5.43; N, 20.19. 
4.1.4.4  (7-Amino-5-methyl-2-phenyl[1,3]oxazolo[5,4-b]pyridin-6-yl)methanol 
(22a)  
White solid; yield: 80%; mp: >350 oC; IR cm-1: 3460 (OH), 3421, 3335 (NH2); 1H NMR (200 
MHz, DMSO-d6) δ: 3.36 (3H, s, CH3), 4.5 (2H, d, J = 5.2 Hz, CH2), 4.87 (1H, t, J = 5.2 Hz, OH), 
6.52 (2H, s, NH2), 7.59-7.62 (3H, m, ArH), 8.10-8.15 (2H, m, ArH); 13C NMR (50 MHz, DMSO-
d6) δ: 22.7 (q) 59.3 (t), 113.9 (s), 127.9 (s), 127.7 (2 x d), 127.3 (2 x d), 128.9 (d), 131.3 (s), 
132.1 (s), 146.3 (s), 152.5 (s), 159.1 (s). Anal. Calcd. for C14H13N3O2: C, 65.87; H, 5.13; N,16.46. 
Found: C, 65.68; H, 5.00; N, 16.60. 
4.1.4.5  (7-amino-2-(4-methoxyphenyl)-5-methyl[1,3]oxazolo[5,4-b]pyridin-6-
yl)methanol (22b)  
White solid; yield: 55%; mp: >350 oC; IR cm-1: 3498 (OH), 3410, 3339 (NH2);1H NMR (200 
MHz, DMSO-d6) δ: 2.47 (3H, s, CH3), 3.86 (3H, s, CH3O), 4.5 (2H, d, J = 5.4 Hz, CH2), 4.86 (1H, 
t, J = 5.4 Hz, OH), 6.44 (2H, s, NH2), 7.16 (2H, d, J = 8.8 Hz, H3' and H5'), 8.08 (2H, d, J = 8.8 Hz, 
H2' and H6'); 3C NMR (50 MHz, DMSO-d6) δ: 22.4 (q), 55.4 (q), 55.9 (t), 114.6 (s), 114.7 (2 x d), 
118.3 (s), 119.2 (s), 128.3 (2 x d), 146.0 (s), 152.6 (s), 157.5 (s), 158.3 (s), 161.6 (s). Anal. 
Calcd. for C15H15N3O3: C, 63.15; H, 5.30; N, 14.73. Found: C, 63.04; H, 5.22; N, 14.81. 
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4.1.4.6  (7-amino-5-methyl-2-(3,4,5-trimethoxyphenyl)[1,3]oxazolo[5,4-
b]pyridin-6-yl)methanol (22c)  
White solid; yield: 78%; mp: >350 oC; IR cm-1: 3496 (OH), 3421, 3335 (NH2); 1H NMR (200 
MHz, DMSO-d6) δ: 3.36 (3H, s, CH3), 3.76 (3H, s, CH3), 3.91 (6H, s, CH3), 4.56 (2H, d, J = 4.6 
Hz, CH2), 4.87 (1H, t, J = 4.6 Hz, OH), 6.53 (2H, s, NH2), 7.40 (2H, s, H2' and H6'); 13C NMR (50 
MHz, DMSO-d6) δ: 22.5 (q) 55.9 (t), 56.0 (2 x q), 60.2 (q), 103.6 (2 x d), 114.7 (s), 118.3 (s), 
122.1 (s), 140.0 (s), 146.2 (s), 153.0 (s), 153.3 (2 x s), 157.2 (s), 158.4 (s). Anal. Calcd. for 
C16H19N3O5: C, 59.12; H, 5.55; N, 12.17;. Found: C, 59.27; H, 5.63; N, 12.02. 
 
4.1.5  General Procedure for the Synthesis of 7-Amino-5-methyl-3-substituted-
3H-[1,2,3]triazolo[4,5-b]pyridine-6-carbaldehyde derivatives (23a-c) and 7-
Amino-5-methyl-2-substituted-[1,3]oxazolo[5,4-b]pyridine-6-carbaldehyde 
derivatives (24a-c)  
To a solution of the suitable 7-amino-5-methyl-3-substituted-3H-[1,2,3]triazolo[4,5-b]pyridin-6-
yl)methanol derivatives 21a-c (1.74 mmol) or (7-amino-5-methyl-2-substituted-
[1,3]oxazolo[5,4-b]pyridin-6-yl)methanol derivatives 22a-c (1.74 mmol) in anhydrous 
dichloromethane (20 mL), Dess-Martin periodinane (1.03 g, 2.44 mmol) was gradually added 
under argon atmosphere. The reaction mixture was stirred at room temperature for 5 hours; 
diethyl ether was added and the organic phase was washed with a 5% solution of sodium 
thiosulfate and a saturated solution of sodium hydrogen carbonate. The organic phase was dried 
over sodium sulfate and the solvent was removed under reduced pressure to give the crude 
carbaldehyde derivative product which was immediately used in the next step. 
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4.1.6  General Procedure for the Synthesis of 5-Methyl-3,8-disubstituted-3H-
[1,2,3]triazolo[4,5-h][1,6]naphthyridine derivatives (5a-l) and 5-Methyl-2,8-
disubstituted[1,3]oxazolo[5,4-h][1,6]naphthyridine derivatives (6a-l)   
To a solution of 7-amino-5-methyl-2-substituted-[1,3]triazolo[5,4-b]pyridine-6-carbaldehyde 
derivatives 23a-c (0.30 mmol) or 7-amino-5-methyl-2-substituted[1,3]oxazolo[5,4-b]pyridine-6-
carbaldehyde derivatives 24a-c (0.30 mmol)  and potassium hydroxide (0.02 g, 0.36 mmol) in 
ethanol or acetone (for derivatives 5d, 5h, 5l,  6d, 6h, 6l), the proper ketone (0.30 mmol) was 
added. The reaction mixture was heated under reflux for 12 h. Then the reaction mixture was 
poured onto crushed ice and the precipitate was filtered off, dried and purified by 
chromatography (DCM/AcOEt 95/5). 
 
4.1.6.1  5-Methyl-3,8-diphenyl-3H-[1,2,3]triazolo[4,5-h][1,6]naphthyridine (5a)  
This compound was obtained from reaction of 23a with acetophenone. White solid; yield: 45%; 
mp: 262.8-263.0 oC; 1H NMR (200 MHz, CDCl3) δ: 3.06 (3H, s, CH3), 7.48-7.65 (6H, m, ArH), 
8.05 (1H, d, J = 8.8 Hz, H7), 8.31-8.40 (4H, m, ArH), 8.54 (1H, d, J = 8.8 Hz, H6); 13C NMR (50 
MHz, CDCl3) δ: 23.1 (q), 119.2 (d), 119.5 (s), 122.2 (2 x d), 128.2 (2 x d), 128.4 (d), 128.9 (2 x 
d), 129.5 (2 x d), 130.7 (d), 133.3 (s), 135.9 (d), 136.5 (s), 137.9 (s), 143.9 (s), 144.1 (s), 161.7 
(s), 162.2 (s). Anal. Calcd for C21H15N5: C, 74.76; H, 4.48; N, 20.76. Found: C, 74.83; H, 4.32; N, 
20.65. 
 
4.1.6.2  8-(2-Methoxyphenyl)-5-methyl-3-phenyl-3H-[1,2,3]triazolo[4,5-
h][1,6]naphthyridine (5b)  
This compound was obtained from reaction of 23a with 2-methoxy-acetophenone. Light yellow 
solid; yield: 42%; mp: 247.7-248.0 oC; 1H NMR (200 MHz, CDCl3) δ: 3.11 (3H, s, CH3), 3.93 
(3H, s, CH3O), 7.07 (1H, d, J = 8.8 Hz, H7), 7.19 (1H, t, J = 7.5 Hz, ArH), 7.45-7.54 (2H, m, 
ArH), 7.59-7.67 (2H, m, ArH), 8.27-8.38 (4H, m, ArH), 8.54 (1H, d, J = 8.8 Hz, H6); 13C NMR 
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(50 MHz, CDCl3) δ: 23.1 (q), 55.7 (q), 111.4 (d), 119.3 (s), 121.5 (d), 122.2 (2 x d), 124.2 (d), 
128.0 (s), 128.4 (d), 129.4 (2 x d), 131.6 (d), 132.7 (d), 133.5 (s), 134.3 (d), 136.6 (s), 143.8 (s), 
144.1 (s), 157.6 (s), 161.7 (s), 162.1 (s). Anal. Calcd for C22H17N5O: C, 71.92; H, 4.66; N, 19.06. 
Found: C, 71.84; H, 4.82; N, 19.19. 
 
4.1.6.3  8-(4-Methoxyphenyl)-5-methyl-3-phenyl-3H-[1,2,3]triazolo[4,5-
h][1,6]naphthyridine (5c)  
This compound was obtained from reaction of 23a with 4-methoxy-acetophenone. White solid; 
yield: 53%; mp: 227.8-228.0 oC; 1H NMR (200 MHz, CDCl3) δ: 3.04 (3H, s, CH3), 3.91 (3H, s, 
CH3O), 7.06 (2H, d, J = 6.9 Hz, ArH), 7.45-7.66 (3H, m, ArH), 7.98 (1H, d, J = 8.9 Hz, H7), 7.32-
8.38 (4H, m, ArH), 8.48 (1H, d, J = 8.9 Hz, H6); 13C NMR (50 MHz, CDCl3) δ: 23.0 (q), 55.5 (q), 
114.3 (2 x d), 118.5 (d), 119.1 (s), 122.2 (2 x d), 128.4 (d), 129.4 (2 x d), 129.8 (2 x d), 130.4 (s), 
133.4 (s), 135.6 (d), 136.6 (s), 144.0 (s), 144.2 (s), 161.2 (s), 161.9 (s), 162.1 (s). Anal. Calcd for 
C22H17N5O: C, 71.92; H, 4.66; N, 19.06. Found: C, 72.02; H, 4.54; N, 18.94. 
 
4.1.6.4  5,8-Dimethyl-3-phenyl-3H-[1,2,3]triazolo[4,5-h][1,6]naphthyridine (5d)  
This compound was obtained from reaction of 23a with acetone. White solid; yield: 56%; mp: 
190.0-190.5 oC; 1H NMR (200 MHz, CDCl3) δ: 2.94 (3H, s, CH3), 3.08 (3H, s, CH3), 7.50-7.67 
(4H, m, ArH), 8.33-8.48 (3H, m, ArH); 13C NMR (50 MHz, CDCl3) δ: 23.0 (q), 28.2 (q), 119.0 
(s), 122.1 (2 x d), 122.8 (d), 128.4 (d), 129.4 (2 x d), 133.1 (s), 135.1 (d), 136.6 (s), 143.7 (s), 
143.8 (s), 162.2 (s), 165.4 (s). Anal. Calcd for C16H13N5: C, 69.80; H, 4.76; N, 25.44. Found: C, 
69.64; H, 4.93; N, 25.52.   
4.1.6.5  3-(4-Methoxyphenyl)-5-methyl-8-phenyl-3H-[1,2,3]triazolo[4,5-
h][1,6]naphthyridine (5e)  
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This compound was obtained from reaction of 23b with acetophenone. White solid; yield: 65%; 
mp: 276.0-277.4 oC; 1H NMR (200 MHz, CDCl3) δ: 3.09 (3H, s, CH3), 3.92 (3H, s, CH3O), 7.13 
(2H, d, J=9.0 Hz, H2’ and H6’), 7.55-7.58 (3H, m, ArH), 8.09-8.21 (3H, m, ArH), 8.38-8.43 (2H, 
m, ArH), 8.60 (1H, d, J = 8.8, H6); 13C NMR (50 MHz, CDCl3) δ: 23.1 (q), 55.6 (q), 114.6 (2 x d), 
119.2 (d), 119.6 (s), 124.0 (2 x d), 128.2 (2 x d), 129.0 (2 x d), 129.6 (s), 130.7 (d), 133.2 (s), 
135.9 (d), 137.9 (s), 144.3 (s), 159.7 (s), 161.8 (s), 162.0 (2 x s). Anal. Calcd for C22H17N5O: C, 
71.92; H, 4.66; N, 19.06. Found: C, 71.98; H, 4.54; N, 19.18. 
 
4.1.6.6  8-(2-Methoxyphenyl)-3-(4-methoxyphenyl)-5-methyl-3H-
[1,2,3]triazolo[4,5-h][1,6]naphthyridine (5f)  
This compound was obtained from reaction of 23b with 2-methoxy-acetophenone. White solid; 
yield: 55%; mp: 215.1-215.4 oC; 1H NMR (200 MHz, CDCl3) δ: 3.09 (3H, s, CH3), 3.91 (3H, s, 
CH3O), 3.93 (3H, s, CH3O), 7.04-7.23 (4H, m, ArH), 7.44-7.53 (1H, m, ArH), 8.17-8.31 (4H, m, 
ArH), 8.53 (1H, d, J = 8.8 Hz, H6); 13C NMR (50 MHz, CDCl3) δ: 23.1 (q), 55.6 (q), 55.7 (q), 
111.4 (d), 114.6 (2 x d), 119.3 (s), 121.4 (d), 123.9 (2 x d), 124.2 (d), 128.0 (s), 129.7 (s), 131.5 
(d), 132.7 (d), 133.2 (s), 134.3 (d), 143.7 (s), 144.1 (s), 157.6 (s), 159.6 (s), 161.6 (s), 161.9 (s). 
Anal. Calcd for C23H19N5O2: C, 69.51; H, 4.82; N, 17.62. Found: C, 69.62; H, 4.74; N, 17.43. 
4.1.6.7  3,8-Bis(4-methoxyphenyl)-5-methyl-3H-[1,2,3]triazolo[4,5-
h][1,6]naphthyridine (5g)  
This compound was obtained from reaction of 23b with 4-methoxy-acetophenone. White solid; 
yield: 60%; mp: 238.9-239.6 oC; 1H NMR (200 MHz, CDCl3) δ: 3.06 (3H, s, CH3), 3.91 (3H, s, 
CH3O), 3.92 (3H, s, CH3O), 7.06-7.15 (4H, m, ArH), 8.04 (1H, d, J = 8.8 Hz, H7), 8.18 (2H, d, J = 
9.0 Hz, ArH), 8.40 (2H, d, J = 9.0 Hz, ArH), 8.53 (1H, d, J = 8.8 Hz, H6); 13C NMR (50 MHz, 
CDCl3) δ: 23.1 (q), 55.5 (q), 55.6 (q), 114.3 (2 x d), 114.6 (2 x d), 118.5 (d), 119.2 (s), 123.9 (2 x 
d), 129.7 (s), 129.8 (2 x d), 130.5 (s), 133.2 (s), 135.7 (d), 143.9 (s), 144.3 (s), 159.6 (s), 161.2 
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(s), 161.9 (2 x s). Anal. Calcd for C23H19N5O2: C, 69.51; H, 4.82; N, 17.62. Found: C, 69.45; H, 
4.93; N, 17.78. 
4.1.6.8  3-(4-Methoxyphenyl)-5,8-dimethyl-3H-[1,2,3]triazolo[4,5-
h][1,6]naphthyridine (5h)  
This compound was obtained from reaction of 23b with acetone. Light yellow solid; yield: 44%; 
mp: 228.0-229.1 oC; 1H NMR (200 MHz, CDCl3) δ: 2.91 (3H, s, CH3), 3.03 (3H, s, CH3), 3.90 
(3H, s, CH3O), 7.11 (2H, d, J = 9.0 Hz, H2' and H6'), 7.48 (1H, d, J = 8.6 Hz, H7), 8.18 (2H, d, J = 
9.0 Hz, H3' and H5'), 8.40 (1H, d, J = 8.6 Hz, H6); 13C NMR (50 MHz, CDCl3) δ: 23.0 (q), 25.7 (q), 
55.6 (q), 114.5 (2 x d), 118.9 (s), 122.7 (d), 123.7 (2 x d), 129.7 (s), 132.8 (s), 135.0 (d), 143.5 
(s), 143.7 (s), 159.6 (s), 161.9 (s), 165.2 (s). Anal. Calcd for C17H15N5O: C, 66.87; H, 4.95; N, 
22.94. Found: C, 66.79; H, 5.03; N, 23.11. 
4.1.6.9  5-Methyl-8-phenyl-3-(3,4,5-trimethoxyphenyl)-3H-[1,2,3]triazolo[4,5-
h][1,6]naphthyridine (5i)  
This compound was obtained from reaction of 23c with acetophenone. White solid; yield: 60%; 
mp: 212.7-213.0 oC; 1H NMR (200 MHz, CDCl3) δ: 3.12 (3H, s, CH3), 3.95 (3H, s, CH3O), 4.02 
(6H, s, CH3Ox2), 7.57-7.60 (3H, m, ArH), 7.69 (2H, s, H2' and H6'), 8.14 (1H, d, J = 8.8 Hz, H7), 
8.40-8.45 (2H, m, ArH), 8.63 (1H, d, J = 8.8 Hz, H6); 13C NMR (50 MHz, CDCl3) δ: 23.3 (q), 56.4 
(2 x q), 61.1 (q), 100.0 (2 x d), 119.3 (d), 119.6 (s), 128.3 (2 x d), 129.0 (2 x d), 131.0 (d), 132.4 
(s), 133.5 (s), 135.9 (d), 137.9 (2 x s), 143.9 (s), 144.2 (s), 153.7 (2 x s), 162.0 (s), 162.1 (s). 
Anal. Calcd for C24H21N5O3: C, 67.44; H, 4.95; N, 16.38.  Found: C, 67.57; H, 4.82; N, 16.23. 
4.1.6.10  8-(2-Methoxyphenyl)-5-methyl-3-(3,4,5-trimethoxyphenyl)-3H-
[1,2,3]triazolo[4,5-h][1,6]naphthyridine (5j)  
This compound was obtained from reaction of 23c with 2-methoxy-acetophenone. White solid; 
yield: 55%; mp: 210.5-211.7 oC; 1H NMR (200 MHz, CDCl3) δ: 3.11 (3H, s, CH3), 3.93 (3H, s, 
CH3O), 3.94 (3H, s, CH3O), 4.02 (6H, s, 2 x CH3O), 7.07 (1H, d, J = 8.8 Hz, H7), 7.16-7.24 (1H, 
m, ArH), 7.46-7.54 (1H, m, ArH), 7.69 (2H, s, H2' and H6'), 8.28- 8.32 (2H, m, ArH), 8.55 (1H, d, 
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J = 8.8 Hz, H6); 13C NMR (50 MHz, CDCl3) δ: 23.3 (q), 55.7 (q), 56.4 (2 x q), 61.1 (q), 99.7 (2 x 
d), 111.4 (d), 119.3 (s), 121.5 (d), 124.3 (d), 127.9 (s), 131.6 (d), 132.4 (s), 132.7 (d), 133.5 (s), 
134.3 (d), 137.9 (s), 143.7 (s), 144.1 (s), 153.7 (2 x s), 157.6 (s), 161.8 (s), 162.1 (s). Anal. Calcd 
for C25H23N5O4: C, 65.63; H, 5.07; N, 15.31.  Found: C, 65.72; H, 4.92; N, 15.23. 
 
4.1.6.11  8-(4-Methoxyphenyl)-5-methyl-3-(3,4,5-trimethoxyphenyl)-3H-
[1,2,3]triazolo[4,5-h][1,6]naphthyridine (5k)  
This compound was obtained from reaction of 23c with 4-methoxy-acetophenone. White solid; 
yield: 45%; mp: 249.5-249.9 oC; 1H NMR (200 MHz, CDCl3) δ: 3.10 (3H, s, CH3), 3.93 (3H, s, 
CH3O), 3.94 (3H, s, CH3O), 4.02 (6H, s, 2 x CH3O), 7.09 (2H, d, J = 8.9 Hz, H3”and H5”), 7.69 (2H, 
s, H2' and H6'), 8.08 (1H, d, J = 8.9 Hz, H7), 8.42 (2H, d, J = 8.9 Hz, H2”and H6”), 8.57 (1H, d, J = 8.9 
Hz, H6); 13C NMR (50 MHz, CDCl3) δ: 23.2 (q), 55.5 (q), 56.4 (2 x q), 61.1 (q), 99.5 (2 x d), 
114.3 (2 x d), 118.4 (d), 119.1 (s), 129.7 (2 x d), 130.3 (s), 132.4 (s), 133.4 (s), 135.5 (d), 137.8 
(s), 143.8 (s), 144.0 (s), 153.6 (2 x s), 161.2 (s), 161.9 (2 x s). Anal. Calcd for C25H23N5O4: C, 
65.63; H, 5.07; N, 15.31. Found: C, 65.48; H, 5.22; N, 15.43. 
 
 
4.1.6.12  5,8-Dimethyl-3-(3,4,5-trimethoxyphenyl)-3H-[1,2,3]triazolo[4,5-
h][1,6]naphthyridine (5l)  
This compound was obtained from reaction of 23c with acetone. Light yellow solid; yield: 57%; 
mp: 238.2-239.0 oC; 1H NMR (200 MHz, CDCl3) δ: 2.95 (3H, s, CH3), 3.08 (3H, s, CH3), 3.94, 
(3H, s, CH3O), 4.01 (6H, s, 2 x CH3O), 7.55 (1H, d, J = 8.6 Hz, H7), 7.69 (2H, s, H2’ and H6’), 8.47 
(1H, d, J = 8.6 Hz, H6); 13C NMR (50 MHz, CDCl3) δ: 23.3 (q), 25.8 (q), 56.4 (2 x q), 61.0 (q), 
99.6 (2 x d), 118.9 (s), 122.9 (d), 132.4 (s), 133.1 (s), 135.1 (d), 137.8 (s), 143.6 (s), 143.8 (s), 
153.6 (2 x s), 162.1 (s), 165.6 (s). Anal. Calcd for C19H19N5O3: C, 62.46; H, 5.24; N, 19.17. Found: 
C, 62.62; H, 5.07; N, 19.01. 
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4.1.6.13  5-Methyl-2,8-diphenyl[1,3]oxazolo[5,4-h][1,6]naphthyridine (6a)  
This compound was obtained from reaction of 24a with acetophenone. White solid; yield: 44%; 
mp: 229.8-230.2 oC; 1H NMR (200 MHz, CDCl3) δ: 3.08 (3H, s, CH3), 7.54-7.58 (6H, m, ArH), 
8.03 (1H, d, J = 8.9 Hz, H7), 8.33-8.45 (4H, m, ArH), 8.60 (1H, d, J = 8.9 Hz, H6); 13C NMR (50 
MHz, CDCl3) δ: 22.2 (q), 118.7 (d), 120.2 (s), 126.9 (s), 127.0 (s), 127.7 (2 x d), 128.2 (2 x d), 
128.8 (2 x d), 128.9 (2 x d), 130.5 (d), 131.6 (d), 135.9 (d), 138.2 (s), 144.5, (s), 156.1 (s), 157.9 
(s), 161.4 (s), 161.5 (s). Anal. Calcd. for C22H15N3O: C, 78.32; H, 4.48; N, 12.46. Found: C, 77.99; 
H, 4.66; N, 12.71. 
 
4.1.6.14  8-(2-Methoxyphenyl)-5-methyl-2-phenyl[1,3]oxazolo[5,4-
h][1,6]naphthyridine (6b)  
This compound was obtained from reaction of 24a with 2-methoxy-acetophenone. Yellow solid; 
yield: 58%; mp: 221.9-222.3 oC; 1H NMR (200 MHz, CDCl3) δ: 3.09 (3H, s, CH3), 3.91 (3H, s, 
CH3O), 7.06 (1H, d, J = 7.5 Hz, ArH), 7.18 (1H, t, J = 7.5 Hz, ArH), 7.44 -7.56 (4H, m, ArH), 
8.12-8.18 (2H, m, ArH), 8.39-8.43 (2H, m, ArH), 8.52 (1H, d, J = 9.0 Hz, H6); 13C NMR (50 
MHz, CDCl3) δ: 22.3 (q), 55.7 (q), 111.4 (d), 120.1 (s), 121.4 (d), 123.6 (d), 127.1 (2 x s), 127.7 
(2 x d), 128.5 (s), 128.9 (2 x d), 131.4 (d), 131.5 (d), 132.5 (d), 134.2 (d), 144.6 (s), 156.0 (s), 
157.5 (s), 157.6 (s), 161.3 (s), 161.7 (s). Anal. Calcd. for C23H17N3O2: C, 75.19; H, 4.66; N, 11.44. 
Found: C, 75.05; H, 4.51; N, 11.62. 
 
4.1.6.15  8-(4-Methoxyphenyl)-5-methyl-2-phenyl[1,3]oxazolo[5,4-
h][1,6]naphthyridine (6c)  
This compound was obtained from reaction of 24a with 4-methoxy-acetophenone. Yellow solid; 
yield: 48%; mp: 243.1-244.5 oC; 1H NMR (200 MHz, CDCl3) δ: 3.06 (3H, s, CH3), 3.92 (3H, s, 
CH3O), 7.07 (2H, d, J = 8.9 Hz, ArH), 7.54-7.58 (3H, m, ArH), 7.98 (1H, d, J = 9.0 Hz, H7), 8.34 
- 8.44 (4H, m, ArH), 8.54 (1H, d, J = 9.0 Hz, H6); 13C NMR (50 MHz, CDCl3) δ: 22.2 (q), 55.5 
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(q), 114.3 (2 x d), 118.1 (d), 119.9 (s), 126.9 (s), 127.0 (s), 127.7 (2 x d), 128.9 (2 x d), 129.8 (2 
x d), 130.7 (s), 131.6 (d), 135.7 (d), 144.7 (s), 155.9 (s), 157.9 (s), 160.9 (s), 161.3 (s), 161.8 (s). 
Anal. Calcd. for C23H17N3O2: C, 75.19; H, 4.66; N, 11.44. Found: C, 75.43; H,4.82; N, 11.19. 
4.1.6.16  5,8-Dimethyl-2-phenyl[1,3]oxazolo[5,4-h][1,6]naphthyridine (6d)  
This compound was obtained from reaction of 24a with acetone. Yellow solid; yield: 40%; mp: 
199.6-200.3 oC; 1H NMR (200 MHz, CDCl3) δ: 2.92 (3H, s, CH3), 3.05 (3H, s, CH3), 7.43-7.57 
(4H, m, ArH), 8.40-8.46 (3H, m, ArH); 13C NMR (50 MHz, CDCl3) δ: 22.1 (q), 25.9 (q), 119.7 
(s), 122.1 (d), 126.6 (s), 127.0 (s), 127.7 (2 x d), 128.9 (2 x d), 131.6 (d), 135.1 (d), 144.3 (s), 
156.0 (s), 157.7 (s), 161.4 (s), 164.9 (s). Anal. Calcd. C17H13N3O: C, 74.17; H, 4.76; N, 15.26. 
Found: C, 74.03; H, 4.92; N, 15.44. 
 
4.1.6.17  2-(4-Methoxyphenyl)-5-methyl-8-phenyl[1,3]oxazolo[5,4-
h][1,6]naphthyridine (6e)  
This compound was obtained from reaction of 24b with acetophenone. Yellow solid; yield: 
42%; mp: 247.3-248.4 oC; 1H NMR (200 MHz, CDCl3) δ: 3.05 (3H, s, CH3), 3.90 (3H, s, CH3O), 
7.05 (2H, d, J = 9.0 Hz, ArH), 7.53-7.59 (3H, m, ArH), 7.99 (1H, d, J = 9.0, H7), 8.32-8.37 (4H, 
m, ArH), 8.55 (1H, d, J = 9.0 Hz, H6); 13C NMR (50 MHz, CDCl3) δ: 22.1 (q), 55.5 (q), 114.4 (2 x 
d), 118.5 (d), 119.5 (s), 120.1 (s), 127.1 (s), 128.2 (2 x d), 128.8 (2 x d), 129.5 (2 x d), 130.5 (d), 
135.9 (d), 138.2 (s), 144.4 (s), 155.3 (s), 157.8 (s), 161.3 (s), 161.6 (s), 162.4 (s). Anal. Calcd. 
C23H17N3O2: C, 75.19; H, 4.66; N, 11.44. Found: C, 75.00; H, 4.83; N, 11.56. 
 
4.1.6.18  8-(2-Methoxyphenyl)-2-(4-methoxyphenyl)-5-methyl[1,3]oxazolo[5,4-
h][1,6]naphthyridine (6f)  
This compound was obtained from reaction of 24b with 2-methoxy-acetophenone. White solid; 
yield: 54%; mp: 230.2-231.6 oC; 1H NMR (200 MHz, CDCl3) δ: 3.07 (3H, s, CH3), 3.90 (6H, s, 2 
x CH3O), 7.02-7.07 (3H, m, ArH), 7.17 (1H, t, J = 7.4 Hz, ArH), 7.47 (1H, t, J = 7.4 Hz, ArH), 
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8.10-8.17 (2H, m, ArH), 8.35 (2H, d, J = 8.7 Hz, ArH), 8.51 (1H, d, J = 8.9 Hz, ArH); 13C NMR 
(50 MHz, CDCl3) δ: 22.2 (q), 55.5 (q), 55.7 (q), 111.3 (d), 114.3 (2 x d), 119.6 (s), 119.9 (s), 
121.3 (d), 123.4 (d), 127.1 (s), 128.5 (s), 129.5 (2 x d), 131.3 (d), 132.4 (d), 134.1 (d), 144.4 (s), 
155.1 (s), 157.5 (s), 157.6 (s), 161.5 (2 x s), 162.3 (s). Anal. Calcd. C24H19N3O3: C, 72.53; H, 4.82; 
N, 10.57. Found: C, 72.67; H, 4.95; N, 10.40. 
 
 
4.1.6.19  2,8-Bis(4-methoxyphenyl)-5-methyl[1,3]oxazolo[5,4-
h][1,6]naphthyridine (6g)  
This compound was obtained from reaction of 24b with 4-methoxy-acetophenone. Yellow solid; 
yield: 52%; mp: 229.0-230.8 oC; 1H NMR (200 MHz, CDCl3) δ: 3.03 (3H, s, CH3), 3.90 (6H, s, 2 
x CH3O), 7.06 (4H, d, J = 8.5 Hz, ArH), 7.95 (1H, d, J = 9.0 Hz, H7), 8.34  (4H, J = 8.5 Hz, ArH), 
8.51 (1H, d, J = 9.0 Hz, H6); 13C NMR (50 MHz, CDCl3) δ: 22.1 (q), 55.4 (2 x q), 114.2 (2 x d), 
114.4 (2 x d), 117.9 (d), 119.5 (s), 119.8 (s), 127.0 (s), 129.5 (2 x d), 129.8 (2 x d), 130.7 (s), 
135.7 (d), 144.4 (s), 155.1 (s), 157.9 (s), 160.8 (s), 161.5 (s), 161.8 (s), 162.4 (s). Anal. Calcd. for 
C24H19N3O3: C, 72.53; H, 4.82; N, 10.57. Found: C, 72.27; H, 4.69; N, 10.69. 
 
4.1.6.20  2-(4-Methoxyphenyl)-5,8-dimethyl[1,3]oxazolo[5,4-
h][1,6]naphthyridine (6h)  
This compound was obtained from reaction of 24b with acetone. Yellow solid; yield: 48%; mp: 
187.3-188.5 oC; 1H NMR (200 MHz, CDCl3) δ: 2.90 (3H, s, CH3), 3.03 (3H, s, CH3), 3.90 (3H, s, 
CH3O), 7.04 (2H, d, J = 9.0 Hz, H3' and H5'), 7.42 (1H, d, J = 8.7 Hz, H7), 8.34-8.43 (3H, m, H2', H6' 
and H6); 13C NMR (50 MHz, CDCl3) δ: 22.1 (q), 25.9 (q), 55.5 (q), 114.4 (2 x d), 119.5 (s), 119.6 
(s), 122.0 (d), 126.6 (s), 129.5 (2 x d), 135.1 (d), 144.0 (s), 155.2 (s), 157.6 (s), 161.6 (s), 162.4 
(s), 164.7 (s). Anal. Calcd. for C18H15N3O2: C, 70.81; H, 4.95; N, 13.76. Found: C, 71.09; H, 5.13; 
N, 13.52. 
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4.1.6.21  5-Methyl-8-phenyl-2-(3,4,5-trimethoxyphenyl)[1,3]oxazolo[5,4-
h][1,6]naphthyridine (6i)  
This compound was obtained from reaction of 24c with acetophenone. Yellow solid; yield: 
45%; mp: 229.1-229.9 oC; 1H NMR (200 MHz, CDCl3) δ: 3.05 (3H, s, CH3), 3.96 (3H, s, CH3O), 
4.00 (6H, s, 2 x CH3O), 7.52-7.59 (3H, m, H3”, H4” and H5”), 7.65 (2H, s, H2’ and H6’), 8.00 (1H, d, 
J=8.9 Hz, H7), 8.31-8.36 (2H, m, H2” and H6”), 8.56 (1H, d, J=8.9 Hz, H6); 13C NMR (50 MHz, 
CDCl3) δ: 22.2 (q), 56.4 (2 x q), 61.0 (q), 104.7 (2 x d), 118.7 (d), 120.3 (s), 121.9 (s), 127.1 (s), 
128.2 (2 x d), 128.9 (2 x d), 130.5 (d), 136.0 (d), 138.2 (s), 140.9 (s), 144.4 (s), 153.5 (2 x s), 
155.9 (s), 157.8 (s), 161.2 (s), 161.6 (s). Anal. Calcd for C25H21N3O4: C, 70.25; H, 4.95; N, 9.83. 
Found: C, 70.49; H, 4.72; N, 9.74.  
 
 
4.1.6.22  8-(2-Methoxyphenyl)-5-methyl-2-(3,4,5-
trimethoxyphenyl)[1,3]oxazolo[5,4-h][1,6]naphthyridine (6j)  
This compound was obtained from reaction of 24c with 2-methoxy-acetophenone. Yellow solid; 
yield: 56%; mp: 191.7-192.0 oC; 1H NMR (200 MHz, CDCl3) δ: 3.09 (3H, s, CH3), 3.91 (3H, s, 
CH3O), 3.95 (3H, s, CH3O), 4.00 (6H, s, 2 x CH3O), 7.06 (1H, d, J = 8.2, ArH), 7.18 (1H, t, J = 
8.2 Hz, ArH), 7.48 (1H, t, J = 8.2 Hz, ArH), 7.69 (2H, s, H2’ and H6’), 8.14 (2H, d, J = 8.9 Hz, 
ArH), 8.54 (1H, d, J = 9.0 Hz, H6); 13C NMR (50 MHz, CDCl3) δ: 22.2 (q), 55.7 (q), 56.4 (2 x q), 
61.0 (q), 104.7 (2 x d), 111.4 (d), 120.1 (s), 121.4 (d), 122.1 (s), 123.6 (d), 127.1 (s), 128.5 (s), 
131.4 (d), 132.4 (d), 134.2 (d), 140.9 (s), 144.5 (s), 153.5 (2 x s), 155.8 (s), 157.5 (s), 157.6 (s), 
161.2 (s), 161.7 (s).Anal. Calcd. for C26H23N3O5: C, 68.26; H, 5.07; N, 9.19. Found: C, 68.35; H, 
5.25; N, 9.01. 
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4.1.6.23  8-(4-Methoxyphenyl)-5-methyl-2-(3,4,5-
trimethoxyphenyl)[1,3]oxazolo[5,4-h][1,6]naphthyridine (6k)  
This compound was obtained from reaction of 24c with 4-methoxy-acetophenone. Yellow solid; 
yield: 48%; mp: 217.4 -217.8 oC; 1H NMR (200 MHz, CDCl3) δ: 3.07 (3H, s, CH3), 3.92 (3H, s, 
CH3O), 3.96 (3H, s, CH3O), 4.02 (6H, s, 2 x CH3O), 7.08 (2H, d, J = 8.9 Hz, H3” and H5”), 7.69 
(2H, s, H2' and H6'), 8.00 (1H, d, J = 9.0 Hz, H7), 8.35 (2H, d, J = 8.9, H2” and H6”), 8.56 (1H, d, J = 
9.0 Hz, H6); 13C NMR (50 MHz, CDCl3) δ: 22.2 (q), 55.5 (2 x q), 56.4 (q), 61.1 (q), 104.8 (2 x d), 
114.3 (2 x d), 118.2 (d), 120.0 (s), 122.0 (s), 127.0 (s), 129.8 (2 x d), 130.7 (s), 135.8 (d), 141.0 
(s), 144.6 (s), 153.5 (2 x s), 155.8 (s), 157.9 (s), 161.1 (s), 161.2 (s), 161.8 (s). Anal. Calcd. for 
C26H23N3O5: C, 68.26; H, 5.07; N, 9.19. Found: C, 68.50; H, 4.89; N, 9.32. 
 
4.1.6.24  5,8-Dimethyl-2-(3,4,5-trimethoxyphenyl)[1,3]oxazolo[5,4-
h][1,6]naphthyridine (6l)  
This compound was obtained from reaction of 24c with acetone. White solid; yield: 40%; mp: 
151.7-152.1 oC; 1H NMR (200 MHz, CDCl3) δ: 2.93 (3H, s, CH3), 3.06 (3H, s, CH3), 3.95, (3H, s, 
CH3O), 4.00 (6H, s, 2 x CH3O), 7.46 (1H, d, J = 8.7 Hz, H7), 7.69, (2H, s, H2’ and H6’), 8.45 (1H, d, 
J = 8.7 Hz, H6); 13C NMR (50 MHz, CDCl3) δ: 22.2 (q), 25.9 (q), 56.4 (2 x q), 61.1 (q), 104.8 (2 x 
d), 119.8 (s), 122.0 (s), 122.2 (d), 126.7 (s), 135.2 (d), 141.0 (s), 144.2 (s), 153.5 (2 x s), 155.8 
(s), 157.6 (s), 161.2 (s), 164.9 (s). Anal. Calcd. for C20H19N3O4: C, 65.74; H, 5.24; N, 11.50. 
Found: C, 65.97; H, 5.02; N, 11.24. 
 
4.1.7  General Procedure for the Synthesis of 5-Methyl-3-substituted-3,9-
dihydro-8H-[1,2,3]triazolo[4,5-h][1,6]naphthyridin-8-one derivatives (7a-c) and 
5-Methyl-2-substituted[1,3]oxazolo[5,4-h][1,6]naphthyridin-8(9H)-one 
derivatives (8a-c)   
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To a suspension of 7-amino-5-methyl-2-substituted-[1,2,3]triazolo[5,4-b]pyridine-6-
carbaldehyde derivative 23a-c (0.42 mmol) or 7-amino-5-methyl-2-substituted-
[1,3]oxazolo[5,4-b]pyridine-6-carbaldehyde derivatives 24a-c (0.42 mmol) in  anhydrous 
ethanol (10 mL), potassium carbonate (1.26 mmol) was added at room temperature. The reaction 
mixture was stirred for few minutes and then triethyl phosphonoacetate (0.25 mL, 1.26 mmol) 
was added. The reaction mixture was refluxed for 12 h. The solvent was removed under reduced 
pressure and ice and water were added (50 mL). The precipitate was filtered off, dried and 
purified by chromatography (DCM/AcOEt 8/2). The poor solubility of compounds 7a-c and 
8a-c prevented 13C NMR spectra from being recorded. 
 
4.1.7.1  5-Methyl-3-phenyl-3,9-dihydro-8H-[1,2,3]triazolo[4,5-
h][1,6]naphthyridin-8-one (7a)  
This compound was obtained from reaction of 23a. Light yellow solid; yield: 60%; mp: 304.5-
305 oC; IR cm-1: 3610 (NH), 1675 (CO); 1H NMR (200 MHz, DMSO-d6) δ: 2.87 (3H, s, CH3), 6.65 
(1H, d, J = 10.0 Hz, H7), 7.57-7.74 (3H, m, ArH and H6), 8.18-8.32 (3H, m, ArH), 13.26 (1H, s, 
NH). Anal. Calcd for C15H11N5O: C, 64.97; H, 4.00; N, 25.26. Found: C, 64.77; H, 4.15; N, 25.38. 
 
4.1.7.2  3-(4-Methoxyphenyl)-5-methyl-3,9-dihydro-8H-[1,2,3]triazolo[4,5-
h][1,6]naphthyridin-8-one (7b)  
This compound was obtained from reaction of 23b. Yellow solid; yield: 55%; mp: 279.1-280.0 
oC; IR cm-1: 3421 (NH), 1669 (CO); 1H NMR (200 MHz, DMSO-d6) δ: 2.80 (3H, s, CH3), 3.87 
(3H, s, CH3O), 6.53 (1H, d, J = 10.0 Hz, H7), 7.23 (2H, d, J = 8.0 Hz H2' and H6'), 8.06 (3H, m, H3', 
H5' and H6), 13.24 (1H, s, NH). Anal. Calcd for C16H13N5O2: C, 62.53; H, 4.26; N, 22.79. Found: C, 
62.65; H, 4.21; N, 22.65. 
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4.1.7.3  5-Methyl-3-(3,4,5-trimethoxyphenyl)-3,9-dihydro-8H-
[1,2,3]triazolo[4,5-h][1,6]naphthyridin-8-one (7c)  
This compound was obtained from reaction of 23c. Yellow solid; yield: 40%; mp: 293.4-294.7 
oC; IR cm-1: 3588 (NH), 1663 (CO); 1H NMR (200 MHz, CDCl3) δ: 2.94 (3H, s, CH3), 3.94 (3H, s, 
CH3O), 4.00 (6H, s, 2 x CH3O), 6.79 (1H, d, J = 9.9 Hz, H7), 7.64 (2H, s, H2' and H6'), 8.11 (1H, d, J 
= 9.9 Hz, H6), 10.36 (1H, s, NH).  Anal. Calcd for C18H17N5O4: C, 58.85; H, 4.66; N, 19.06. Found: 
C, 58.97; H, 4.54; N, 18.90. 
 
4.1.7.4  5-Methyl-2-phenyl[1,3]oxazolo[5,4-h][1,6]naphthyridin-8(9H)-one (8a)  
This compound was obtained from reaction of 24a. White solid; yield: 45%; mp: 199.4-200.5 oC; 
IR cm-1: 3400 (NH), 1630 (CO); 1H NMR (200 MHz, CDCl3) δ: 2.88 (3H, s, CH3), 6.72 (1H, d, J 
= 10.0 Hz, H7), 7.54-7.65 (3H, m, H3’, H4’ and H5’), 8.07 (1H, d, J = 10.0 Hz, H6), 8.22-8.26 (2H, m, 
H2’ and H6’), 9.98 (1H, s, NH). Anal. Calcd.  for C16H11N3O2: C, 69.31; H, 4.00; N, 15.15. Found: C, 
69.20; H, 4.12; N, 15.34.  
 
4.1.7.5  2-(4-Methoxyphenyl)-5-methyl[1,3]oxazolo[5,4-h][1,6]naphthyridin-
8(9H)-one (8b)  
This compound was obtained from reaction of 24b. Yellow solid; yield: 62%; mp: 276.6-276.8 
oC; IR cm-1: 3593 (NH), 1670 (CO); 1H NMR (200 MHz, CDCl3) δ: 2.87 (3H, s, CH3), 3.91 (3H, s, 
CH3O), 6.69 (1H, d, J = 10.0 Hz, H7), 7.04 (2H, d, J = 8.9 Hz, H3' and H5'), 8.05 (1H, d, J = 10.0 
Hz, H6), 8.18 (2H, d, J = 8.9 Hz, H2' and H6'), 9.77 (1H, s, NH). Anal. Calcd. for C17H13N3O3: C, 
66.44; H,4.26; N,13.67. Found: C, 66.30; H, 4.39; N, 13.50. 
 
4.1.7.6  5-Methyl-2-(3,4,5-trimethoxyphenyl)[1,3]oxazolo[5,4-
h][1,6]naphthyridin-8(9H)-one (8c)  
This compound was obtained from reaction of 24c. White solid; yield: 48%; mp: 273.1-273.8 oC; 
IR cm-1: 3590 (NH), 1650 (CO); 1H NMR (200 MHz, DMSO-d6) δ: 2.80 (3H, s, CH3), 3.79 (3H, s, 
 48 
CH3O), 3.93 (6H, s, 2 x CH3O), 6.57 (1H, d, J = 9.9 Hz, H7), 7.51 (2H, s, H2' and H6'), 8.22 (1H, d, J 
= 9.9 Hz, H6), 12.65 (1H, s, NH). Anal. Calcd. for C19H17N3O5: C, 62.12; H, 4.66; N, 11.44. Found: 
C, 62.40; H 4.48, N, 11.28. 
 
4.2. Photophysical characterization and photooxidation study 
4.2.1. Spectroscopic and kinetic characterization of the triplet excited state, by 
LFP 
LP 920 Edinburgh Instrument photolysis system has been employed to carry out all the detection 
experiments of the transient species. The minimum response time of the detection system was of 
about 10 ns. The laser beam (a Nd/YAG operated at l = 355 nm) was focused on a 3 mm wide 
circular area of the cell and the first 5 mm in depth were analyzed at a right angle geometry. The 
incident pulse energies used were 30 mJ per pulse. The spectra were reconstructed point from 
time profiles taken each 5 nm. The absorbance at 355 nm A355 was ~1.0 over 1 cm. Ar-saturated 
or air-equilibrated solutions were used. The sample was renewed after few laser shots. 
Temperature was 295 K.  
 
4.2.2. Generation of 1O 2 and its trapping by 9,10-anthracenedipropionic acid in 
aqueous acetonitrile 
Quantum yield measurements for ADPA consumption (FR) were measured by irradiating 2 mL 
2.5 10-5 M of 6e and 5h (acetonitrile: water = 3:2 solutions) in 1cm optical path cuvettes in the 
presence of 1.1 10-4 M concentration of ADPA, after flushing with oxygen. The lamp source was 
a focalized 150 W high-pressure mercury arc fitted with a transmittance filter (transmission 400 
nm). Potassium ferrioxalate was used as the actinometer. [57,58] 
 
4.3 Biology 
4.3.1 Compound solubilization in DMSO 
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[1,2,3]Triazolo[4,5-h][1,6]naphthyridines 5a-l, [1,3]oxazolo[5,4-h][1,6]naphthyridines 6a-l, 
and [1,2,3]triazolo[4,5-h][1,6]naphthyridin-8-ones 7a-c, [1,3]oxazolo[5,4-h][1,6]naphthyridin-
8-ones 8a-c were resuspended in dimethyl sulfoxide (DMSO), which was chosen among organic 
solvents as it can be administered to human cell lines in small percentage without induction of 
cytotoxicity. Since within each series of compounds, some derivatives showed solubility issues, 
further studies were conducted only on compounds that completely dissolved and were stable in 
DMSO. 
 
4.3.2 Spectrophotometric determinations  
All spectrophotometric measures were performed using UV-Vis Perkin Elmer instrument 
(Lambda 25). For all the compounds, absorption spectra, molar extinction coefficients (ε) and 
determination of maxima peaks (λmax) were carried out in 20 mM PB, pH 7.4. 
4.3.3 Irradiation procedures 
Irradiation experiments were performed in a photochemical multirays reactor, equipped with 10 
UV lamps (3660 Å), emitting at 365 nm (Helios Italquartz, Italy). The spectral irradiance of the 
source was 5 mw/cm2 as measured with a UVX Radiometer (UVP, Upland, CA, USA). 
 
4.3.4 Cellular cytotoxicity and phototoxicity 
Cytotoxic effects were determined by MTT assay. Derivatives reported in Table 4 were 
dissolved and diluted into working concentrations with DMSO. All cell lines were grown and 
maintained according to manufacturer’s instructions (https://www.lgcstandards-atcc.org). Cells 
were plated into 96-microwell plates to a final volume of 100 µL and allowed an overnight 
period for attachment. The following day, the tested compounds were added to each well to 
reach a 0.5% final concentration of DMSO per well; each concentration was tested in triplicate. 
Compounds were incubated for 5 min, then cells were washed in 1x PBS (100 µL) and fresh 
medium was added. In phototoxicity experiments, immediately after medium removal, cells were 
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irradiated on ice for 5 min at 365 nm, corresponding to 1.5 J/cm2, in a photochemical multirays 
reactor and incubated at 37 °C for 72 h. Control cells (without any compound but with 0.5% 
DMSO) were treated in the exact same conditions. Cell survival was evaluated by MTT assay: 
10 µL of freshly dissolved solution of MTT (5 mg/mL in PBS) were added to each well, and 
after 4 h of incubation, MTT crystals were solubilized in solubilization solution (10% sodium 
dodecyl sulphate (SDS) and 0.01 M HCl). After overnight incubation at 37 °C, absorbance was 
read at 540 nm. Data were expressed as mean values of at least three individual experiments 
conducted in triplicate. The percentage of cell survival was calculated as follows: cell survival = 
(Awell − Ablank)/(Acontrol − Ablank) × 100, where blank denotes the medium without cells. 
Each experiment was repeated at least three times. 
4.3.5 Reactive oxygen species (ROS) detection in cells 
The cell-permeant 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) is a chemically 
reduced form of fluorescein used as an indicator for reactive oxygen species (ROS) in cells. 
Oxidation results in the formation of fluorescent DCF, which is maximally excited at 495 nm and 
emits at 520 nm. MCF7 cells (3x104) were plated in 96 wells plates medium 24 h before the 
assay was performed, so that cells reached 80–90% of confluence on the day of the experiment. 
RPMI medium containing 10% FBS was removed and compounds were incubated at different 
concentrations for 30 min in phenol red and serum free medium to avoid subsequent probe 
oxidation. H2DCFDA probe (10 µM) was added to cell medium and incubated for 15 minutes 
prior to irradiation (1.5 J/cm2). Control plates that did not undergo irradiation were also included 
in each experiment. NAC (N-acetyl-L-cysteine) was used as antioxidant control compound; 
NAC prevention of ROS formation was performed at different concentrations. Phorbol-12-
myristate-13-acetate (PMA) was used as a validated ROS-inducer compound. ROS production 
was monitored at Victor X2 Multilabel plate reader, lamp filter 485 nm and emission filter 535 
nm (Perkin Elmer Italia, Milan). 
4.3.6 Flow cytofluorimetry 
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For cell cycle distribution analysis only adherent cells were fixed in 70% EtOH and incubated at 
4 °C for 30 min in staining solution containing 50 μg/mL of propidium iodide, 50 mg/mL of 
RNase, and 0.05% Igepal in PBS. Samples (at least 30000 events) were analyzed on an LRS 2 
instrument using FACS DIVA Software (BD Bioscience) and analyzed with Flow Jo (Tree Star). 
The rate of apoptotic cells was measured by the amount of cell surface exposure of 
phosphatidylserine. MCF7 cells in exponential growth were treated with different concentrations 
of the test compounds for 4 h. Cells were pelleted, washed in 1x PBS and stained with FITC 
annexin V according to the manufacturer’s instructions (Annexin V-FITC Apoptosis Detection 
Kit, eBioscience, Thermo Fisher Scientific Inc.). Subsequently, cells were counterstained with 
propidium iodide (PI), according to the manufacturer’s instructions (Annexin V-FITC Apoptosis 
Detection Kit, eBioscience, Thermo Fisher Scientific Inc.). Samples were analyzed on an LRS 2 
instrument using FACS DIVA Software (BD Bioscience) and analyzed with Flow Jo (Tree Star). 
4.3.7 Confocal imaging 
For confocal imaging cells were seeded on glass cover-slips 24 h prior compound administration. 
Cells were washed in 1x PBS, fixed in paraformaldehyde (PFA, 2%) and mounted in Vectashield 
mounting medium (DBA ITALIA, Milan, Italy). Images were captured at a Leica SP2 or SP5 
confocal microscope (63x objective, Green HeNe (Helium Neon) laser λex 543 nm, λem 560-620 
nm, Blue Argon laser λex 488 nm, λem 500-530 nm and 405 diode laser λex 405 nm, λem 415-460 nm).  
4.3.8 Analysis of mitochondrial dysfunction by confocal microscopy 
Mitochondria were labelled in live-cells using Mitotracker Orange CMTM-ROS (Thermo Fisher 
Scientific, Milan, Italy). MCF7 cells were plated on glass slides (4x105). After 24 h the complete 
medium was removed and replaced with phenol red and serum free medium containing the 
mitochondrial probe (150 nM), the probe was incubated 45 min prior to addition of compounds 
and photoactivation. After irradiation cells were washed in 1x PBS, fixed in paraformaldehyde 
(PFA, 2%) and mounted in Vectashield mounting medium (DBA ITALIA, Milan, Italy). Nuclei 
were stained with Nuclear Green dye LCS1 (Abcam, λex 503 nm, λem 526 nm). Phorbol-12-
myristate-13-acetate (PMA) was used as a validated ROS-inducer compound. Images were 
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captured at a Leica SP2 confocal microscope (63x objective, Green HeNe (Helium Neon) laser 
λex 543 nm, λem 560-620 nm and the Blue Argon laser λex 488 nm, λem 500-530 nm for the nuclear 
staining).  
 
4.3.9 Analysis of lysosomal activation by confocal microscopy 
Lysosomes were labelled in live-cells using Lysotracker Green DND 26 (Thermo Fisher 
Scientific, Milan, Italy). MCF7 cells were plated on glass slides (4x105).  After 24 h the complete 
medium was removed and replaced with phenol red and serum free medium containing the 
mitochondrial probe (175 nM), the probe was incubated 45 min prior to addition of compounds 
and photoactivation. After irradiation cells were washed in 1x PBS, fixed in paraformaldehyde 
(PFA, 2%) and mounted in Vectashield mounting medium (DBA ITALIA, Milan, Italy). 
Phorbol-12-myristate-13-acetate (PMA) was used as a validated ROS-inducer compound. 
Images were captured at a Leica SP2 confocal microscope (63x objective, Blue Argon laser λex 
488 nm, λem 500-530 nm for the nuclear staining). 
 
4.3.10 Statistical Analysis.  
Pairwise comparisons between means of different groups and experiments were performed using 
a Student t-test (two tailed, unpaired, unpaired) where, for each couple of normally distributed 
populations (i.e. treated vs untreated), the null hypothesis that the means are equal was verified. 
The difference between two subsets of data was considered statistically significant if the Student 
t-test gives a significance level P (P value) less than 0.01. 
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